Pazopanib | GW786034;GSK-VEG10003;GW786034B | VEGFR | PDGFR | c-Fms | c-Kit

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	99%+
Masitinib	+ Kit, IC50: 200 nM		99%+
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		97%
Ki8751	++ c-Kit, IC50: 40 nM		99%
Tivozanib	++ c-Kit, IC50: 78 nM		99%+
Pazopanib	+ c-Kit, IC50: 140 nM		99%
Sitravatinib	+++ Kit, IC50: 6 nM		99%+
Pexidartinib	+++ Kit, IC50: 10 nM		99%+
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	85%
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		99%+
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	99%
AZD2932	+++ c-Kit, IC50: 9 nM		99%
Axitinib	++++ Kit, IC50: 1.7 nM		98%
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	99%+
Sunitinib	✔	FLT3	98%
OSI-930	+ Kit, IC50: 80 nM		99%+
Telatinib	++++ c-Kit, IC50: 1 nM		99%+
Dasatinib monohydrate	++ c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM	Src	98%
Dasatinib	++ c-Kit (D816V), IC50: 37 nM c-Kit (wt), IC50: 79 nM	Src	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				97%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			VEGFR,mTOR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	99%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	99%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	PDGFR,FGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms/CSF1R,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	FLT3,RET	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line Ren-01 cells MKN45 cells SKOV3ip1 cells HeyA8 cells MOECs (murine ovarian endothelial cells) 786-O cells Human aortic endothelial cells (HAoEC) Human aortic endothelial cells (HAoEC) Daoy cells MEB-Med-8A cells HCT116 cells SW480 cells HT29 cells	Concentration	Treated Time	Description	References
Ren-01 cells	2 µM	24 h	To evaluate the effect of Pazopanib on Ren-01 cells, results showed that Pazopanib alone or in combination with MEK inhibitor reduced phosphorylation of MEK1/2 and ERK1/2.	Br J Cancer. 2016 Oct 11;115(8):920-928.
MKN45 cells	10 μM to 100 μM	6 days	To evaluate the effect of Pazopanib on epithelial-mesenchymal transition (EMT) in MKN45 cells, results showed that EMT was not induced in vitro.	Cancer Res. 2020 Jan 15;80(2):304-318.
SKOV3ip1 cells	0.001-100 μM	3-4 h	Pazopanib treatment reduced VEGFR-2 phosphorylation, especially at higher doses (≥1 μM).	Mol Cancer Ther. 2010 Apr;9(4):985-95.
HeyA8 cells	0.001-100 μM	3-4 h	Pazopanib treatment reduced VEGFR-2 phosphorylation, but the effect was more pronounced at higher doses.	Mol Cancer Ther. 2010 Apr;9(4):985-95.
MOECs (murine ovarian endothelial cells)	0.001, 1, 10 μM	4-5 h	Pazopanib treatment reduced endothelial cell migration in a dose-dependent manner following VEGF stimulation.	Mol Cancer Ther. 2010 Apr;9(4):985-95.
786-O cells	8 µM		To evaluate the effect of Pazopanib on the proliferation of 786-O cells	Oncoimmunology. 2020 Mar 11;9(1):1736793.
Human aortic endothelial cells (HAoEC)	5 µg/mL	3 h	Pazopanib abolished the intermittent hypoxia (IH)-induced increase in LDL passage through an endothelial cell monolayer.	Int J Mol Sci. 2022 Jun 24;23(13):7012.
Human aortic endothelial cells (HAoEC)	5 µg/mL	4 h	Pazopanib abolished the intermittent hypoxia (IH)-induced monocyte migration through an endothelial cell monolayer.	Int J Mol Sci. 2022 Jun 24;23(13):7012.
Daoy cells	15 μM	24 h	Pazopanib reduced the migratory capacity of Daoy cells and altered cell morphology, leading to decreased cell-cell connections and a more spindle-shaped phenotype.	J Cell Mol Med. 2022 Dec;26(23):5832-5845.
MEB-Med-8A cells	15 μM	12 h	Pazopanib reduced the migratory capacity of MEB-Med-8A cells and caused morphological changes, leading to decreased cell-cell connections and loss of adhesive properties.	J Cell Mol Med. 2022 Dec;26(23):5832-5845.
HCT116 cells	10 nM	14-16 h	Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels	Cancer Res. 2016 May 15;76(10):3014-24.
SW480 cells	10 nM	14-16 h	Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels	Cancer Res. 2016 May 15;76(10):3014-24.
HT29 cells	10 nM	14-16 h	Inhibition of the kinase function of VEGFR1 by pazopanib or SU5416 also had no effect on pAKT or pERK1/2 levels	Cancer Res. 2016 May 15;76(10):3014-24.

Species Nude mice Mice Nude mice Mice Nude mice Mice	Animal Model SNU5 gastric carcinoma xenograft model Ren-02 renal cell carcinoma xenograft model MKN45 and SNU5 gastric cancer xenograft models Rag2−/−IL2rg−/− double knockout mice SKOV3ip1 and HeyA8 ovarian cancer models C57BL/6J mice	Administration	Dosage	Frequency	Description	References
Nude mice	SNU5 gastric carcinoma xenograft model	Oral	100 mg/kg	Once daily for 8 days	To study the effect of pazopanib on MET signaling, results showed that pazopanib increased the pY1235-MET:MET and pY1356-MET:MET ratios, and tivantinib reversed this effect.	Clin Cancer Res. 2016 Jul 15;22(14):3683-94.
Mice	Ren-02 renal cell carcinoma xenograft model	Oral	100 mg/kg	Twice daily, until the end of the experiment	To evaluate the anti-tumor effect of Pazopanib in a renal cell carcinoma xenograft model, results showed that Pazopanib alone or in combination with MEK inhibitor reduced phosphorylation of MEK1/2 and ERK1/2 and inhibited tumor growth.	Br J Cancer. 2016 Oct 11;115(8):920-928.
Nude mice	MKN45 and SNU5 gastric cancer xenograft models	Oral	100 mg/kg	Once daily for 14 days (MKN45) or 15 days (SNU5)	To evaluate the effect of Pazopanib on epithelial-mesenchymal transition (EMT) in gastric cancer xenograft models, results showed a significant shift toward a mesenchymal phenotype in pazopanib-treated MKN45 xenografts, while the SNU5 model showed no significant changes.	Cancer Res. 2020 Jan 15;80(2):304-318.
Mice	Rag2−/−IL2rg−/− double knockout mice	Oral gavage	30mg/kg	Once daily, continuous treatment	Evaluating the efficacy of Pazopanib in ccRCC patient-derived xenograft models, results showed that Pazopanib alone did not significantly affect tumor progression, but when combined with sAXL, it significantly reduced tumor growth and vessel density.	Cancer Res. 2019 Nov 15;79(22):5758-5768
Nude mice	SKOV3ip1 and HeyA8 ovarian cancer models	Oral	100 mg/kg	Every other day, continued until mice became moribund	Single agent pazopanib therapy reduced tumor weight by 82% in the SKOV3ip1 model and 28% in the HeyA8 model. Combination therapy with metronomic topotecan resulted in a 79-84% reduction in tumor weight.	Mol Cancer Ther. 2010 Apr;9(4):985-95.
Mice	C57BL/6J mice	Gavage	30 mg/kg	Once daily for 14 days	Pazopanib prevented the intermittent hypoxia (IH)-induced VE-cadherin cleavage and aortic wall thickening.	Int J Mol Sci. 2022 Jun 24;23(13):7012.

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01027598	Non Small Cell Lung Cancer	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Suburban Hem Onc Lawrenceville, Georgia, United States, 30045 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Family Cancer Center Collerville, Tennessee, United States, 38119 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Virginia Cancer Institute Richmond, Virginia, United States, 23235 收起 <<
NCT01027598	-		Completed	-	-
NCT01407562	Unspecified Adult Solid Tumor ... 展开 >>- Protocol Specific Breast Cancer - Female 收起 <<	Phase 1	Active, not recruiting	June 2019	United States, New Jersey ... 展开 >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 收起 <<
NCT01280201	Advanced/Metastatic Neuroendoc... 展开 >>rine Tumors 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> Institut Català d'Oncologia L'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain Hospital Universitari Vall d'Hebron Barcelona, Spain Centro Integral Oncológico Clara Campal Madrid, Spain Hospital Clínico San Carlos Madrid, Spain Hospital Universitario 12 de Octubre Madrid, Spain Hospital Universitario Ramón y Cajal Madrid, Spain Hospital Universitario Virgen de la Victoria Málaga, Spain Hospital Universitari Son Espases Palma de Mallorca, Spain Hospital Universitario Virgen del Rocío Sevilla, Spain Hospital Clínico Universitario Lozano Blesa Zaragoza, Spain 收起 <<
NCT01391611	-		Terminated(Lack of efficacy - ... 展开 >>Futility endpoint reached) 收起 <<	-	-
NCT02348398	Cervical Cancer	Phase 2	Withdrawn	-	-
NCT00350727	Glioma	Phase 2	Completed	-	-
NCT01391611	Gastrointestinal Stromal Tumor... 展开 >> (GIST) 收起 <<	Phase 2	Terminated(Lack of efficacy - ... 展开 >>Futility endpoint reached) 收起 <<	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT00370513	Carcinoma, Hepatocellular	Phase 1	Completed	-	United States, California ... 展开 >> GSK Investigational Site San Francisco, California, United States, 94115 Hong Kong GSK Investigational Site Hong Kong, Hong Kong Taiwan GSK Investigational Site Taipei, Taiwan, 100 收起 <<
NCT00350727	-		Completed	-	-
NCT00387205	Carcinoma, Renal Cell	Phase 1	Completed	-	-
NCT00334282	-		Completed	-	-
NCT00334282	Carcinoma, Renal Cell	Phase 3	Completed	-	-
NCT00866528	Lung Cancer, Non-Small Cell	Phase 1	Completed	-	United States, Illinois ... 展开 >> GSK Investigational Site Chicago, Illinois, United States, 60637 United States, Ohio GSK Investigational Site Columbus, Ohio, United States, 43210 United Kingdom GSK Investigational Site Sutton, Surrey, United Kingdom, SM2 5PT GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN 收起 <<
NCT00459381	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> University of California Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94115 United States, Maryland National Cancer Institute Neuro-Oncology Branch Bethesda, Maryland, United States, 20814 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT01524848	Gastrointestinal Stromal Tumor... 展开 >>s 收起 <<	Phase 2	Completed	-	Denmark ... 展开 >> Aarhus University Hospital, dept. of Oncology Aarhus, Denmark, DK-8000 Aarhus C Herlev Hospital, dept. of Oncology Herlev, Denmark, 2730 Finland Helsinki University Hospital, dept. of oncology Helsingfors, Finland, FI-00029 Kuopio University Hospital Cancer Center Kuopio, Finland, FI-70029 Germany Klinik für Interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg Berlin, Germany, 13125 Universitätsklinikum Essen, Innere klinik und Poliklinik Essen, Germany, DE-45122 Studienzentrale chirurgische klinik, Universitäts medizin Mannheim Mannheim, Germany, DE-68167 Norway Dept of Oncology, Haukeland University Hospital Bergen, Norway, N-5021 Norwegian Radium Hospital Oslo, Norway, N-0310 Dept of Oncology, St Olav Hospital Trondheim, Norway, N-7006 Sweden Dept of Oncology, Sahlgrenska University Hospital Gothenburg, Sweden, SE-413 45 Dept of Oncology, Linköping University Hospital Linköping, Sweden, SE-581 85 Dept of Oncology, Skane University Hospital Lund, Sweden, SE-221 85 Radiumhemmet, Karolinska University Hospital Stockholm, Sweden, SE-171 76 Dept of Oncology, Norrland University Hospital Umeå, Sweden, SE-901 85 Dept of Oncology, Academic Hospital Uppsala, Sweden, SE-751 85 收起 <<
NCT01548144	Advanced Cancers	Phase 1	Active, not recruiting	April 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00459381	-		Completed	-	-
NCT01566747	Renal Cell Carcinoma	Phase 2	Active, not recruiting	September 2018	Ireland ... 展开 >> Beaumont Hospital Dublin, Leinster, Ireland Mater Misericordiae University Hospital Dublin, Leinster, Ireland Mater Private Hospital Dublin, Leinster, Ireland Cork University Hospital Cork, Ireland The Adelaide & Meath Hospital Dublin incorporating the National Children's Hospital Dublin, Ireland Galway University Hospital Galway, Ireland Mid-Western Regional Hospital Limerick, Ireland Waterford Regional Hospital Waterford, Ireland Sweden Karolinska University Hospital Stockholm, Sweden 收起 <<
NCT00401583	Carcinoma, Renal Cell	Phase 1	Completed	-	United States, New Hampshire ... 展开 >> GSK Investigational Site Lebanon, New Hampshire, United States, 03756 Singapore GSK Investigational Site Singapore, Singapore, 119074 收起 <<
NCT01442662	Leiomyosarcoma	Phase 2	Unknown	September 2017	France ... 展开 >> Institut de Cancérologie de l'Ouest/Cantre Paul Papin Recruiting Angers, France, 49933 Contact: Patrick Soulie, MD 33 2 41 35 27 00 patrick.soulie@ico.unicancer.fr Principal Investigator: Patrick Soulie, MD Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Binh Bui Nguyen, MD 33 5 56 33 38 13 bui@bergonie.org Principal Investigator: Binh Bui Nguyen, MD Centre François Baclesse Recruiting Caen, France, 14076 Contact: Corinne Delcambre, MD 33 2 31 45 51 24 c.delcambre@baclesse.fr Principal Investigator: Corinne Delcambre, MD Centre Jean Perrin Recruiting Clermont Ferrand, France, 63011 Contact: Jacques-Olivier Bay, Pr 33 4 73 27 80 80 jacques-olivier.bay@cjp.fr Principal Investigator: Jacques-Olivier Bay, Pr Centre G.F Leclerc Recruiting Dijon, France, 21034 Contact: Nicolas Isambert, MD 33 3 80 73 75 28 nisambert@cgfl.fr Principal Investigator: Nicolas Isambert, MD Centre Oscar Lambret Recruiting Lille, France, 59020 Contact: Nicolas Penel, MD 33 3 20 29 59 59 ext 7956 n-penel@o-lambret.fr Principal Investigator: Nocolas Penel, MD Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Isabelle Ray-Coquard, MD 04 78 78 27 72 ray@lyon.fnclcc.fr Principal Investigator: Isabelle Ray-Coquard, MD Institut Paoli Calmettes Not yet recruiting Marseille, France, 13273 Contact: François Bertucci, Pr 33 4 91 22 35 37 bertuccif@marseille.fnclcc.fr Principal Investigator: François Bertucci, Pr CHU Timone Recruiting Marseille, France, 13385 Contact: Florence Duffaud, MD 33 4 91 38 57 08 florence.duffaud@mail.ap-hm.fr Principal Investigator: Florence Duffaud, MD Centre Val d'Aurelle Paul Lamarque Recruiting Montpellier, France, 34298 Contact: Didier Cupissol, MD 33 4 67 61 81 83 dcupissol@valdorel.fnclcc.fr Principal Investigator: Didier Cupissol, MD Institut de Cancérologie de l'Ouest/Centre René Gauducheau Recruiting NANTES Saint Herblain, France, 44806 Contact: Emmanuelle Bompas, MD 33 2 40 67 99 76 emmanuelle.bompas@ico.unicancer.fr Principal Investigator: Emmanuelle Bompas, MD Centre Antoine Lacassagne Recruiting Nice, France, 06189 Contact: Antoine Thyss, Pr 33 4 92 03 15 38 antoine.thyss@nice.fnclcc.fr Principal Investigator: Antoine Thyss, Pr Institut Curie - Hôpital Claudius Regaud Recruiting Paris, France, 75005 Contact: Sophie Piperno- Neumann, MD 33 1.44.32.46.81 sophie.piperno-neumann@curie.net Principal Investigator: Sophie Piperno-Neumann, MD Institut Jean Godinot Recruiting Reims, France, 51056 Contact: Jean-Christophe Eymard, MD 33 3.26.50.43.92 jc.eymard@reims.fnclcc.fr Principal Investigator: Jean-Christophe Eymard, MD Centre Henri Becquerel Recruiting Rouen, France, 76038 Contact: Cécile Guillemet, MD 33 2 32 08 22 38 C.Guillemet@rouen.fnclcc.fr Principal Investigator: Cécile Guillemet, MD Institut Curie - Hopital René Huguenin Recruiting Saint Cloud, France, 92210 Contact: Etienne Brain, MD 33 1 47 11 15 15 ext 18.75 etienne.brain@curie.net Principal Investigator: Etienne Brain, MD Institut de Cancérologie de la Loire Recruiting St Priest en jarez, France, 42270 Contact: Olivier Collard, MD 33 4 77 91 70 34 olivier.collard@icloire.fr Principal Investigator: Olivier Collard, MD Centre Paul Strauss Not yet recruiting Strasbourg, France, 67065 Contact: Thierry Petit, Pr 33 3.88.25.24.56 tpetit@strasbourg.fnclcc.fr Principal Investigator: Thierry Petit, Pr Institut Claudius Regaud Recruiting Toulouse, France, 31052 Contact: Christine Chevreau, MD 05 61 42 41 74 chevreau.christine@claudiusregaud.fr Principal Investigator: Christine Chevreau, MD Centre Alexis Vautrin Recruiting Vandoeuvre les Nancy, France, 54511 Contact: Maria Rios, MD 33 3 83 59 83 31 m.rios@nancy.fnclcc.fr Principal Investigator: Maria Rios, MD Institut Gustave Roussy Recruiting Villejuif, France, 94805 Contact: Patricia Pautier, MD 33 1 42 11 45 17 pautier@igr.fr Principal Investigator: Patrica Pautier, MD 收起 <<
NCT02691767	Refractory Solid Tumors	Not Applicable	Unknown	December 2018	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT02307474	Clear Cell Renal Cell Carcinom... 展开 >>a Renal Cell Carcinoma 收起 <<	Not Applicable	Withdrawn(Funding Unavailable)	-	United States, Ohio ... 展开 >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 收起 <<
NCT03334409	Clear Cell Renal Cell Carcinom... 展开 >>a Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 2	Recruiting	June 1, 2021	United States, Florida ... 展开 >> Mayo Clinic in Florida Not yet recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Caroline Merillat 904-953-3237 Merillat.Caroline@mayo.edu Principal Investigator: Richard W. Joseph United States, Illinois Illinois CancerCare-Peoria Recruiting Peoria, Illinois, United States, 61615 Contact: Carrie Geoffroy 309-243-3000 cgeoffroy@illinoiscancercare.com Principal Investigator: Madhuri Bajaj United States, Iowa Iowa-Wide Oncology Research Coalition NCORP Recruiting Des Moines, Iowa, United States, 50309 Contact: Andrea Zarling 515-241-3305 aczarling@iora.org Principal Investigator: Joshua C. Lukenbill United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referrals Office 855-776-0015 Principal Investigator: Lance C. Pagliaro Metro Minnesota Community Oncology Research Consortium Recruiting Saint Louis Park, Minnesota, United States, 55416 Contact: Elizabeth J. Wagner 952-993-1555 elizabeth.wagner@parknicollet.com Principal Investigator: David King United States, North Dakota Sanford Medical Center Fargo Not yet recruiting Fargo, North Dakota, United States, 58104 Contact: Melissa Burgard 701-234-2718 melissa.burgard@sanfordhealth.org Principal Investigator: Preston D. Steen United States, Ohio Columbus NCI Community Oncology Research Program Not yet recruiting Columbus, Ohio, United States, 43215 Contact: Deborah A. Shaw 614-488-3310 debby@columbusccop.org Principal Investigator: Timothy D. Moore 收起 <<
NCT01855724	Cholangiocarcinoma ... 展开 >> Gallbladder Carcinoma Biliary Carcinoma 收起 <<	Phase 2	Terminated	-	Greece ... 展开 >> 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital Athens, Greece, 11522 Dept of Medical Oncology, 251 General Air Force Hospital Athens, Greece, 11525 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio" Athens, Greece, 11527 Oncology Dept, 2nd Surgyc Clinic, Aretaieio Hospital Athens, Greece, 11528 Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra" Athens, Greece, 11528 Division of Oncology, 2nd Dept of Internal Medicine, Propaedeutic, University Hospital "Attikon" Athens, Greece, 12462 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Hygeia Hospital Athens, Greece, 15123 1st Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 2nd Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 Dept of Medical Oncology, University Hospital of Heraklion Heraklion, Greece, 71110 Dept of Medical Oncology, Ioannina University Hospital Ioannina, Greece, 45500 Division of Oncology, Dept of Internal Medicine, University Hospital of Patras Patras, Greece, 26504 Dept of Medical Oncology, Papageorgiou General Hospital Thessaloniki, Greece, 56429 Dept of Medical Oncology, Thermi Clinic S.A Thessaloniki, Greece, 57001 2nd Dept of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki Thessaloníki, Greece, 54645 收起 <<
NCT01247571	Recurrent Uterine Corpus Sarco... 展开 >>ma Uterine Carcinosarcoma 收起 <<	Phase 2	Completed	-	-
NCT01247571	-		Completed	-	-
NCT01513187	Advanced Renal Cell Carcinoma	Phase 1 Phase 2	Active, not recruiting	October 2018	Spain ... 展开 >> Instituto Catalán de Oncología, Hospitalet del Llobregat Hospitalet de Llobregat, Barcelona, Spain, 08097 Centro Integral Oncológico Clara Campal Sanchinarro, Sanchinarro - Madrid, Spain, 28050 Hospital del Mar Barcelona, Spain, 08003 Hospital Clínic Barcelona, Spain, 08036 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Hospital Central de Asturias Oviedo, Spain, 33066 Hospital Son Espases Palma, Spain, 07010 Clinica Univ. Navarra Pamplona, Spain, 31008 Hospital Virgen de la Macarena Sevilla, Spain, 41009 Hospital Virgen del Rocio Sevilla, Spain, 41013 Hospital Virgen de la Salud Toledo, Spain, 45004 IVO Valencia, Spain, 46009 收起 <<
NCT00731211	-		Completed	-	-
NCT00731211	Renal Cell Carcinoma	Phase 2	Completed	-	United States, California ... 展开 >> San Francisco Oncology Associates San Francisco, California, United States, 94115 United States, Florida Florida Cancer Specialists Fort Myers, Florida, United States, 33901 Watson Clinic Center for Cancer Care and Research Lakeland, Florida, United States, 33805 Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 Gulfcoast Oncology Associates St. Petersburg, Florida, United States, 33705 United States, Georgia Medical Oncology Associates of Augusta Augusta, Georgia, United States, 30901 Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Kentucky Baptist Hospital East Louisville, Kentucky, United States, 40207 United States, Maine Central Maine Medical Center Lewiston, Maine, United States, 04240 United States, Michigan Grand Rapids Clinical Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Missouri St. Louis Cancer Care Chesterfield, Missouri, United States, 63017 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Virginia Cancer Institute Richmond, Virginia, United States, 23235 收起 <<
NCT01059656	Dermatofibrosarcomas of DARIER... 展开 >> FERRAND(DFSP) 收起 <<	Phase 2	Terminated(Decision of Study P... 展开 >>rincipal Investigator) 收起 <<	-	France ... 展开 >> Hôpital Saint-Louis - Service de Dermatologie (Pole POPS) Paris, France, 75010 收起 <<
NCT01639911	Malignant Neoplasm of Breast ... 展开 >> CNS Malignancy Malignant Neoplasm of Gastrointestinal Tract Genitourinary Neoplasms Malignancy and Gender Unspecified Head and Neck Neoplasms Melanoma Malignant Neoplasm of Thorax 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> University of Illinois Cancer Center Chicago, Illinois, United States, 60612 收起 <<
NCT01995981	-		Completed	-	Netherlands ... 展开 >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6525 GA United Kingdom Royal Marsden Hospital London, United Kingdom 收起 <<
NCT01165385	Solid Tumors ... 展开 >>Metastatic Cancer 收起 <<	Phase 1	Completed	-	France ... 展开 >> Centre François BACLESSE Caen, France, 14076 Centre Georges François LECLERC Dijon, France, 21079 Centre Léon Berard Lyon, France, 69373 CEDEX 08 Centre René Gauducheau Nantes Saint Herblain, France, 44805 Institut Curie Paris, France, 75248 收起 <<
NCT01713296	SCLC	Phase 2	Completed	-	Greece ... 展开 >> "Agioi Anargyroi" Anticancer Hospital of Athens Athens, Greece "IASO" General Hospital of Athens Athens, Greece 401 Military Hospital of Athens Athens, Greece Air Forces Military Hospital of Athens Athens, Greece University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece Heraklion, Greece "Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology Piraeus, Greece "Papageorgiou" Hospital of Thessaloniki Thessaloniki, Greece "Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology Thessaloniki, Greece 收起 <<
NCT01552356	Solid Neoplasm	Phase 1	Active, not recruiting	-	United States, Florida ... 展开 >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT02383251	Ovarian Cancer	Phase 2	Recruiting	December 2018	France ... 展开 >> ICO Paul Papin Active, not recruiting Angers, France, 49933 Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Anne Floquet, MD 5 56 33 33 33 ext 033 a.floquet@bordeaux.unicancer.fr Polyclinique Bordeaux Nord Active, not recruiting Bordeaux, France, 33300 Centre François Baclesse Recruiting Caen, France, 14000 Contact: Emmanuel Sevin, MD 2 31 45 53 97 ext 0033 e.sevin@baclesse.unicancer.fr Centre Jean Perrin Active, not recruiting Clermont-ferrand, France, 63000 Centre Hospitalier de Dax Enrolling by invitation Dax, France, 40107 Centre Georges François Leclerc Active, not recruiting Dijon, France, 21079 Hôpital André Mignot Recruiting Le Chesnay, France, 78157 Contact: Didier MAYEUR, MD 1 39 63 91 33 ext 0033 dmayeur@ch-versailles.fr Centre Jean Bernard - Clinique Victor Hugo Recruiting Le Mans, France, 72000 Contact: Hugues BOURGEOIS, MD 2 43 47 94 94 ext 0033 h.bourgeois@cjb72.org Centre Oscar Lambret Active, not recruiting Lille, France, 59200 Centre Léon Bérard Enrolling by invitation Lyon, France, 69373 Institut Paoli Calmettes Recruiting Marseille, France, 13009 Contact: Magali PROVANSAL, MD 4 91 22 37 40 ext 0033 provansalm@ipc.unicancer.fr Hôpital de Mont-de-Marsan Active, not recruiting Mont-de-marsan, France, 40024 ICM Val d'Aurelle Recruiting Montpellier, France, 34298 Contact: Michel FABBRO, MD 4 67 61 30 63 ext 0033 michel.fabbro@icm.unicancer.fr ORACLE - Centre d'Oncologie de Gentilly Recruiting Nancy, France, 54100 Contact: Dominique SPAETH, MD 3 83 93 50 05 ext 0033 oncomed@wanadoo.fr Centre Catherine de Sienne Recruiting Nantes, France, 44202 Contact: Alain LORTHOLARY, MD 2 28 27 21 71 ext 0033 lortholary.alain@catherinedesienne.fr Centre Antoine Lacassagne Enrolling by invitation Nice, France, 06189 Centre Hospitalier Régional d'Orléans Active, not recruiting Orléans, France, 45067 Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Cochin Active, not recruiting Paris, France, 75014 Clinique Francheville Active, not recruiting Perigueux, France, 20004 Centre Hospitalier Lyon Sud Recruiting Pierre Benite, France, 69495 Contact: Benoît YOU, MD 4 78 86 43 18 ext 0033 benoit.you@chu-lyon.fr Hôpital Privé des Côtes d'Armor Recruiting Plerin Sur Mer, France, 22190 Contact: Anne-Claire HARDY-BESSARD, MD 2 96 75 22 16 ext 0033 ac.hardy@clin-armoricaine.fr "Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie" Enrolling by invitation Poitiers, France, 86021 ICO Centre René Gauducheau Active, not recruiting Saint-herblain, France, 44805 Hôpitaux Universitaires de Strasbourg Enrolling by invitation Strasbourg, France, 67000 Centre Paul Strauss Active, not recruiting Strasbourg, France, 67065 Centre Hospitalier de Thonon-les-Bains Recruiting Thonon-les-Bains, France, 74203 Contact: Francesco DEL PIANO, MD 4 50 83 20 65 ext 0033 f-delpiano@ch-hopitauxduleman.fr ICL Institut de Cancérologie de Lorraine Recruiting Vandoeuvre-les-nancy, France, 54511 Contact: Marie-Christine KAMINSKY, MD 3 83 59 83 63 ext 0033 mc.kaminsky@nancy.unicancer.fr 收起 <<
NCT01235962	Cancer	Phase 3	Active, not recruiting	April 15, 2019	-
NCT01466972	Breast Cancer ... 展开 >> Breast Neoplasm 收起 <<	Phase 2	Active, not recruiting	December 2019	United States, California ... 展开 >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 United States, Connecticut Yale University School of Medicine/Yale Cancer Center New Haven, Connecticut, United States, 06520 收起 <<
NCT01436227	Von Hippel-Lindau Syndrome	Phase 2	Active, not recruiting	January 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02207309	Sarcoma	Phase 2	Terminated(poor recruitment)	-	Germany ... 展开 >> Ludwig-Maximilians University of Munich, Klinikum Großhadern Munich, Bavaria, Germany, 81377 收起 <<
NCT01613846	Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT02367651	Sarcoma, Soft Tissue	Phase 2	Withdrawn(Study cancelled With... 展开 >>drawn before enrollment of any participants) 收起 <<	May 2018	-
NCT01262820	Lung Cancer	Phase 2	Completed	-	United States, North Carolina ... 展开 >> North Carolina Cancer Hospital at U of North Carolina at CH Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT01262820	-		Completed	-	-
NCT03628131	Relapsed Pediatric Solid Tumor... 展开 >> Refractory Pediatric Solid Tumor 收起 <<	Phase 1 Phase 2	Not yet recruiting	July 2025	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung 82-2-3410-3529 kwsped@skku.edu Principal Investigator: Ki Woong Sung 收起 <<
NCT00945477	-		Terminated(Slow enrollment)	-	-
NCT00945477	Prostate Cancer	Phase 2	Terminated(Slow enrollment)	-	United States, Illinois ... 展开 >> Illinois CancerCare Bloomington, Illinois, United States, 61701 Illinois CancerCare Ottawa, Illinois, United States, 61350 Illinois CancerCare Pekin, Illinois, United States, 61554 Illinois Cancer Care Peoria, Illinois, United States, 61615 收起 <<
NCT01767636	Carcinoma of the Collecting Du... 展开 >>cts of Bellini Chromophobe Renal Cell Carcinoma Kidney Medullary Carcinoma Kidney Oncocytoma Metastatic Renal Cell Cancer Papillary Renal Cell Carcinoma Recurrent Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Stage IV Renal Cell Cancer 收起 <<	Phase 2	Active, not recruiting	May 16, 2019	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT02810756	Pharmacokinetics of Pazopanib	Early Phase 1	Completed	-	Netherlands ... 展开 >> Netherlands Cancer Institute Amsterdam, North Holland, Netherlands, 1066 CX 收起 <<
NCT01179269	Non-small Cell Lung Cancer	Phase 2	Withdrawn(The study was stoppe... 展开 >>d because the research team was unable to enroll any participants) 收起 <<	-	-
NCT01498458	-		Completed	-	-
NCT01238770	Epithelial Ovarian Cancer	Phase 1 Phase 2	Completed	-	Germany ... 展开 >> Marienkrankenhaus Hamburg Hamburg, Germany, 22087 Universitäts-Frauenklinik Heidelberg, Germany, 69120 Klinikum Konstanz Gynäkologie und Geburtshilfe Konstanz, Germany, 78464 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde Mainz, Germany, 55131 Universitätsfrauenklinik Tübingen Klinik für Gynäkologie und Geburtshilfe Tübingen, Germany, 72076 收起 <<
NCT02089802	Locally Advanced Renal Cell Ca... 展开 >>rcinoma Metastatic Renal Cell Carcinoma 收起 <<	Phase 2	Terminated(Early termination d... 展开 >>ue to lack of recruitment) 收起 <<	-	Germany ... 展开 >> Gesundheitszentrum Holzminden Holzminden, Niedersachsen, Germany, 37603 Private Practice Kamann Leipzig, Sachsen, Germany, 04357 Private Practice Geiges Berlin, Germany, 10719 收起 <<
NCT00929903	Childhood Central Nervous Syst... 展开 >>em Choriocarcinoma Childhood Central Nervous System Embryonal Tumor Childhood Central Nervous System Germ Cell Tumor Childhood Central Nervous System Germinoma Childhood Central Nervous System Mixed Germ Cell Tumor Childhood Central Nervous System Teratoma Childhood Central Nervous System Yolk Sac Tumor Metastatic Childhood Soft Tissue Sarcoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Central Nervous System Embryonal Tumor Recurrent Childhood Soft Tissue Sarcoma Recurrent Childhood Visual Pathway Glioma Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60614 United States, Indiana Indiana University Medical Center Indianapolis, Indiana, United States, 46202 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, New York Columbia University Medical Center New York, New York, United States, 10032 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Baylor College of Medicine Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 收起 <<
NCT01543802	Sarcoma, Soft-tissue	Phase 2	Unknown	June 2018	Germany ... 展开 >> Klinikum Frankfurt-Höchst Recruiting Frankfurt am Main, Germany, 65929 Contact: Hans-Günter Derigs, MD +49-69-31063320 derigs@klinikumfrankfurt.de Principal Investigator: Hans-Günter Derigs, MD German Cancer Research Center, Medical PET Group - Biological Imaging Recruiting Heidelberg, Germany, 69120 Contact: Antonia Prof. Dr. Antonia Dimitrakopoulou-Strauss, MD +49-6221-422500 a.dimitrakopoulou-strauss@dkfz.de Principal Investigator: Antonia Antonia Dimitrakopoulou-Strauss, MD University Hospital Heidelberg / National Centre for Tumor Diseases Recruiting Heidelberg, Germany, 69120 Contact: Gerlinde Egerer, MD +49-6221-568002 Gerlinde.Egerer@med.uni-heidelberg.de Principal Investigator: Gerlinde Egerer, MD Sub-Investigator: Stefan Froehling, MD University Hospital Mannheim, Dpt. of Surgery Recruiting Mannheim, Germany, 68135 Contact: Ulrich Ronellenfitsch, MD +49-621-3831501 ulrich.ronellenfitsch@umm.de Principal Investigator: Peter Hohenberger, MD 收起 <<
NCT01498458	Metastatic Breast Cancer	Phase 1	Completed	-	Germany ... 展开 >> GBG Forschungs GmbH Neu-Isenburg, Germany, 63263 收起 <<
NCT01265940	Advanced Urothelial Cancer of ... 展开 >>Bladder After Failure of Platinum-containing Therapy. 收起 <<	Phase 1 Phase 2	Completed	-	Germany ... 展开 >> Lukaskrankenhaus Neuss, Germany, 41464 收起 <<
NCT01064310	Carcinoma, Renal Cell	Phase 3	Completed	-	-
NCT01064310	-		Completed	-	-
NCT01205230	Cancer	Phase 4	Completed	-	United States, New Jersey ... 展开 >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, South Carolina GSK Investigational Site Greenville, South Carolina, United States, 29605 收起 <<
NCT01608009	Ovarian Neoplasm	Phase 1	Completed	-	United Kingdom ... 展开 >> Imperial College Healthcare NHS Trust London, United Kingdom Southend University Hospital NHS Foundation Trust Southend, United Kingdom 收起 <<
NCT01797874	SCLC	Phase 2	Active, not recruiting	December 2017	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT01330966	Chondrosarcoma ... 展开 >> Metastatic Chondrosarcoma 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 United States, Illinois Edward Cancer Center Naperville, Illinois, United States, 60540 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Texas MD Anderson Houston, Texas, United States, 77030 United Kingdom University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre Edgbaston, Birmingham, United Kingdom, B15 2TH 收起 <<
NCT01205230	-		Completed	-	-
NCT01257750	Corneal Neovascularization	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts Eye and Ear Infirmary Boston, Massachusetts, United States, 02114 收起 <<
NCT02300545	Sarcoma, Soft Tissue ... 展开 >> Soft Tissue Sarcoma 收起 <<	Phase 2	Recruiting	June 30, 2020	United States, Arizona ... 展开 >> Mayo Clinic - Phoenix Recruiting Phoenix, Arizona, United States, 85054 Contact: Kelly Curtis, MD 480-301-8000 curtis.kelly1@mayo.edu Principal Investigator: Kelly Curtis, MD United States, Florida Mayo Clinic - Jacksonville Recruiting Jacksonville, Florida, United States, 32224 Contact: Steven Attia, DO 904-953-2000 attia.steven@mayo.edu Principal Investigator: Steven Attia, DO United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Mark Agulnik, MD 312-695-0990 mark.agulnik@nm.org Principal Investigator: Mark Agulnik, MD United States, Iowa University of Iowa Recruiting Iowa City, Iowa, United States, 52242 Contact: Mohammed Milhem, MD 319-356-2197 mohammed-milhem@uiowa.edu Principal Investigator: Mohammed Milhem, MD United States, Minnesota Mayo Clinic - Rochester Recruiting Rochester, Minnesota, United States, 55905 Contact: Scott Okuno, MD 507-451-1120 okuno.scott@mayo.edu Principal Investigator: Scott Okuno, MD United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Brian A Van Tine, M.D., Ph.D. 314-747-8475 bvantine@wustl.edu Principal Investigator: Brian Van Tine, M.D., Ph.D. Sub-Investigator: Douglas Adkins, M.D. Sub-Investigator: Loren Michel, M.D. Sub-Investigator: Caron Rigden, M.D. Sub-Investigator: Tanya Wildes, M.D. Sub-Investigator: Angela Hirbe, M.D., Ph.D. United States, Wisconsin University of Wisconsin Clinical Science Center Recruiting Madison, Wisconsin, United States, 53792 Contact: Howard H Bailey, M.D. 608-890-3563 mjolin@uwcarbone.wisc.edu Principal Investigator: Howard H Bailey, M.D. Sub-Investigator: Thomas McFarland, M.D. 收起 <<
NCT01257750	-		Completed	-	-
NCT01692496	Advanced and / or Metastatic L... 展开 >>iposarcoma 收起 <<	Phase 2	Completed	-	Germany ... 展开 >> HELIOS Klinikum Berlin-Buch (Sarkomzentrum Berlin-Brandenburg) Berlin, Germany, D-10707 Universitätsklinikum EssenInnere Klinik (Tumorforschung) Essen, Germany, D-45147 Medizinische Hochschule Hannover (Zentrum Innere Medizin) Hannover, Germany, D-30625 Universitätsmedizin Mannheim (Sarkomzentrum) Manheim, Germany, D-68169 Klinikum Großhadern der LMU Universität München (Med. Klinik und Poliklinik II) Munich, Germany, D-80336 Spain Hospital Central de Asturias Oviedo, Asturias, Spain, 33011 Hospital Universitario de Canarias La Laguna, Islas Canarias, Spain, 38320 Hospital de Navarra Pamplona, Navarra, Spain, 31008 Complejo Hospitalario Universitario de Vigo Vigo, Pontevedra, Spain, 36204 Hospital Vall d'Hebrón Barcelona, Spain, 08035 Hospital 12 de Octubre Madrid, Spain, 28041 Hospital Universitari Son Espases Palma de Mallorca, Spain, 07010 Hospital Universitario Virgen del Rocío Sevilla, Spain, 41013 Instituto Valenciano de Oncología Valencia, Spain, 46009 Hospital Miguel Servet Zaragoza, Spain, 50009 收起 <<
NCT03200717	Advanced Renal Cell Carcinoma ... 展开 >> Metastatic Renal Cell Carcinoma 收起 <<	Phase 2	Recruiting	August 27, 2021	-
NCT01506596	Liposarcoma S... 展开 >>urgically Unresectable Liposarcoma Metastatic Liposarcoma 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, District of Columbia Washington Cancer Institute Washington, District of Columbia, United States, 20010 United States, Idaho Kootenai Cancer Center Post Falls, Idaho, United States, 83854 United States, Illinois Oncology Specialists, SC Niles, Illinois, United States, 60714 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Tennessee West Clinic Memphis, Tennessee, United States, 38120 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01506596	-		Completed	-	-
NCT01339871	Advanced Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02393820	Salivary Gland Carcinoma	Phase 2	Unknown	August 2018	France ... 展开 >> Institut de Cancérologie de l'Ouest Paul Papin Angers, France, 49933 CHU Bordeaux Bordeaux, France, 33075 Centre Jean Perrin Clermont-Ferrand, France, 63011 Centre Georges François Leclerc Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Centre Val d'Aurelle Paul Lamarque Montpellier, France, 34298 Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75231 Centre Hospitalier St Joseph Paris, France, 75674 Centre Eugène Marquis Rennes, France, 35042 Institut Curie site St Cloud Saint Cloud, France, 92210 Institut Cancérologie de l'Ouest Saint-herblain, France, 48805 Centre Paul Strauss Strasbourg, France, 67065 Gustave Roussy Villejuif, France, 94 收起 <<
NCT01107665	Stage III Melanoma ... 展开 >> Stage IV Melanoma Unresectable Melanoma 收起 <<	Phase 2	Active, not recruiting	January 2019	United States, California ... 展开 >> Chao Family Comprehensive Cancer Center Orange, California, United States, 92868 收起 <<
NCT01130805	Gastric Cancer	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT01956669	Solid Tumours	Phase 2	Recruiting	April 1, 2021	-
NCT02066285	Solitary Fibrous Tumor ... 展开 >> Extraskeletal Myxoid Chondrosarcoma 收起 <<	Phase 2	Unknown	June 2018	Spain ... 展开 >> H. Universitario de Canarias Recruiting Tenerife, Santa Cruz de Tenerife, Spain, 38320 Contact: Josefina Cruz Principal Investigator: Josefina Cruz, MD Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain Principal Investigator: López Pousa, MD Hospital La Paz Recruiting Madrid, Spain Contact: Andrés Redondo Principal Investigator: Andrés Redondo, MD Hospital Ramón y Cajal Recruiting Madrid, Spain Contact: M. Ángeles Vaz, MD Principal Investigator: M. Ángeles Vaz, MD H. Son Espases Recruiting Mallorca, Spain Contact: Javier Martín, MD Principal Investigator: Javier Martín Broto, MD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain, 41013 Principal Investigator: Pilar Sancho Marques, MD H. Miguel Servet Recruiting Zaragoza, Spain Principal Investigator: Javier Martínez Trufero, Ph.M. 收起 <<
NCT01813136	Thyroid Carcinoma	Phase 2	Recruiting	June 2018	France ... 展开 >> CHU Angers Recruiting Angers, France, 49933 Principal Investigator: Vincent ROHMER, MD Sub-Investigator: Frédéric ILLOUZ, MD Sub-Investigator: Sandrine LABOUREAU-SOARES BARBOSA, MD Sub-Investigator: Patrice RODIEN, MD CHU Bordeaux Recruiting Bordeaux, France, 33075 Principal Investigator: Alain RAVAUD, MD Sub-Investigator: Laurence DIGUE, MD Sub-Investigator: Marine GROSS-GOUPIL, MD Sub-Investigator: Amandine QUIVY, MD Sub-Investigator: Denis SMITH, MD Sub-Investigator: Nathalie TRUFLANDIER, MD Institut Bergonié Recruiting Bordeaux, France, 33076 Principal Investigator: Yann GODBERT, MD Sub-Investigator: Françoise BONICHON, MD Sub-Investigator: Antoine ITALIANO, MD Centre François Baclesse Recruiting Caen, France, 14076 Principal Investigator: Stéphane BARDET, MD Sub-Investigator: Renaud CIAPPUCCINI, MD CHRU Lille Hôpital Claude Huriez Recruiting Lille, France, 59037 Principal Investigator: Christine DOCAO, MD Sub-Investigator: Maria-Claire MIGAUD, MD Centre Leon Berard Recruiting Lyon, France, 69373 Principal Investigator: Christelle DE LA FOUCHARDIERE, MD Hôpital de la Timone APHM Recruiting Marseille, France, 13385 Principal Investigator: Patricia NICCOLI, MD Sub-Investigator: Charlotte DUPUIS, MD Centre Antoine Lacassagne Recruiting Nice, France, 06189 Principal Investigator: Danielle BENISVY, MD Sub-Investigator: Esma SAADA-BOUZID, MD Hôpital Saint-Louis APHP Recruiting Paris, France, 75010 Principal Investigator: Damien POUESSEL, MD Sub-Investigator: Stéphane CULINE, MD Sub-Investigator: Marie-Elisabeth TOUBERT, MD Sub-Investigator: Cécile CHOUGNET, MD Hôpital de la Pitié Salpêtrière APHP Recruiting Paris, France, 75651 Principal Investigator: Johanna WASSERMANN, MD Sub-Investigator: Laurence LEENHARDT, MD Sub-Investigator: Jean-Philippe SPANO, MD Sub-Investigator: Camille BUFFET, MD Institut Jean Godinot Recruiting Reims, France, 51726 Principal Investigator: Audrey DALAC, MD Sub-Investigator: Sandrine FIEFFE-COQUET, MD Sub-Investigator: Jean-Marie POCHART, MD Sub-Investigator: Claire SCHVARTZ, MD Institut Claudius Régaud Recruiting Toulouse, France, 31052 Principal Investigator: Slimane ZERDOUD, MD Sub-Investigator: Jean-Pierre DELORD, MD Institut Gustave Roussy Recruiting Villejuif, France, 94805 Principal Investigator: Sophie LEBOULLEUX, MD Sub-Investigator: Eric BAUDIN, MD Sub-Investigator: Amandine BERDELOU, MD Sub-Investigator: Martin SCHLUMBERGER, MD 收起 <<
NCT01649778	-		Completed	-	-
NCT01253369	Small Cell Lung Cancer ... 展开 >> Lung Cancer SCLC 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT03592472	Renal Cell Carcinoma	Phase 3	Recruiting	January 17, 2022	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Parikh Mamta United States, Kentucky Norton Cancer Institute, Norton Healthcare Pavilion Not yet recruiting Louisville, Kentucky, United States, 40202 Contact: Kalebasty Arash United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Matrana Marc United States, Nebraska GU Research Network/Urology Cancer Center Recruiting Omaha, Nebraska, United States, 68130 Contact: Nordquist Luke Nebraska Cancer Specialists Recruiting Omaha, Nebraska, United States, 68130 Contact: Hauke Ralph United States, New York Northwell Health/Monter Cancer Center Recruiting Lake Success, New York, United States, 11042 Contact: Bradley Thomas United States, Ohio Precision Cancer Research/Dayton Physicians Network - Treatment Recruiting Kettering, Ohio, United States, 45409 Contact: Bane Charles United States, Pennsylvania St. Luke's Hospital Recruiting Easton, Pennsylvania, United States, 18045 Contact: Faroun Yacoub United States, Texas HOPE Cancer Center of East Texas Recruiting Tyler, Texas, United States, 75701 Contact: Lee Arielle United States, Washington Medical Oncology Associates, PS (dba Summit Cancer Centers) Recruiting Spokane, Washington, United States, 99208 Contact: Arvind Chaudhry Korea, Republic of National Cancer Center - Center For Prostate Cancer Not yet recruiting Goyang-si, Korea, Republic of, 10408 Contact: Jinsoo Chung CHA Bundang Medical Center, CHA University Not yet recruiting Seongnam-si, Korea, Republic of, 13496 Contact: Chan Kim Severance Hospital, Yonsei University Health System - Medical Oncology Not yet recruiting Seoul, Korea, Republic of, 03722 Contact: Sun Young Rha Asan Medical Center - University of Ulsan College of Medicin Not yet recruiting Seoul, Korea, Republic of, 05505 Contact: Jae Lyun Lee Samsung Medical Center - Hematology-Oncology Not yet recruiting Seoul, Korea, Republic of, 06351 Contact: Se Hoon Park 收起 <<
NCT01876082	Progressive Desmoids Tumors	Phase 2	Recruiting	July 2020	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, Aquitaine, France, 33000 Contact: ITALIANO Antoine, MD a.italiano@bordeaux.unicancer.fr Principal Investigator: ITALIANO Antoine, MD 收起 <<
NCT01392352	Renal Cell Carcinoma ... 展开 >> Soft Tissue Sarcoma Glioblastoma Ovarian Cancer Cervical Cancer Breast Cancer Non-small Cell Lung Cancer Small Cell Lung Cancer Pancreatic Cancer Melanoma Gastrointestinal Cancer 收起 <<	Phase 2	Terminated(Following DMC revie... 展开 >>w, due to slow recruitment of evaluable patients.) 收起 <<	-	United Kingdom ... 展开 >> Cambridge University Hospitals NHS Foundation Trust Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ 收起 <<
NCT01253369	-		Completed	-	-
NCT01158521	Clear Cell Renal Cell Carcinom... 展开 >>a Stage I Renal Cell Cancer Stage II Renal Cell Cancer Stage III Renal Cell Cancer 收起 <<	Phase 2	Completed	-	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT01184326	Solid Tumor K... 展开 >>idney Cancer 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01158521	-		Completed	-	-
NCT03660930	Soft Tissue Sarcoma	Phase 1 Phase 2	Not yet recruiting	February 28, 2021	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore 206-606-6425 romoore@seattlecca.org Principal Investigator: Lee Cranmer, MD 收起 <<
NCT02203760	Relapsed or Metastatic Uterine... 展开 >> Leiomyosarcomas or Carcinosarcomas 收起 <<	Phase 2	Unknown	June 2016	Germany ... 展开 >> Praxisklinik für Krebsheilkunde für Frauen Drs. Kittel /Klare / Wetzel Not yet recruiting Berlin, Germany, 10367 Contact: Peter Klare, Dr. med. +4930/ 5548 9336 info@drklare.de Contact: Steffen Gläser, Dr. med. Principal Investigator: Peter Klare, Dr. med. Sub-Investigator: Steffen Gläser, Dr. med. Charité Campus Virchow-Klinikum Universitätsmedizin Berlin Not yet recruiting Berlin, Germany, 13353 Contact: Jalid Sehouli, Professor Dr. med. +4930/ 450 564 002 jalid.sehouli@charite.de Contact: Radoslav Chekorov, Dr. med. +4930/450-664399 radoslav.chekerov@charite.de Principal Investigator: Jalid Sehouli, Prof. Dr. med. Sub-Investigator: Radoslav Chekorov, Dr. med. Klinikum Chemnitz gGmbH Frauen- und Kinderklinik Not yet recruiting Chemnitz, Germany, 09116 Contact: Petra Krabisch 4937133322121 p.krabisch@skc.de Contact: Katja Tittmann k.tittmann@skc.de Principal Investigator: Petra Krabisch, Dr. med. Sub-Investigator: Katja Tittmann, Dr. med. Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden Klinik für Frauenheilkunde und Geburtshilfe Not yet recruiting Dresden, Germany, 01807 Contact: Ulrich Canzler, Dr. med. +49351/458-18076 Ulrich.Canzler@uniklinikum-dresden.de Contact: Karin Kast, Dr. med. +49351/458-18076 Principal Investigator: Ulrich Canzler, Dr. med. Sub-Investigator: Karin Kast, Dr. med. Kliniken-Essen-Mitte Evang. Huyssens-Stiftung Klinik für Senologie / Brustzentrum Not yet recruiting Essen, Germany, 45136 Contact: Phillip Harter, Dr. med. p.harter@kliniken-essen-mitte.de Contact: Florian Heitz, Dr. med. f.heitz@kliniken-essen-mitte.de Principal Investigator: Phillip Harter, Dr. med. Sub-Investigator: Florian Heitz, Dr. med. Universitätsklinikum Freiburg Not yet recruiting Freiburg, Germany, 79106 Contact: Beate Rautenberg, Professor Dr. med. +49761/ 270-3126 beate.rautenberg@uniklinik-freiburg.de Contact: Annette Hasenburg, Professor Dr. med. 49761/270-3168 annette.hasenburg@uniklinik-freiburg.de Principal Investigator: Beate Rautenberg, Prof. Dr. med. Sub-Investigator: Annette Hasenburg, Prof. Dr. med. Ernst-Moritz-Arndt-Universität Greifswald (Sauerbruchstr.) Recruiting Greifswald, Germany, 17475 Praxis Prof. Dr. med. Lück / Dr. Schrader / Dr. Noeding Not yet recruiting Hannover, Germany, 30177 Contact: Hans-Joachim Lück, Dr. med. +49511/ 6 55 52 80 hlueck@goph.de Contact: Iris Schrader, Dr. med. +49511/ 65555280 Info@gyn-onko-praxis-hannover.de Principal Investigator: Hans-Joachim Lück, Dr. med. Sub-Investigator: Iris Schrader, Dr. med. Universitätsklinikum Schleswig-Holstein Campus Kiel Klinik für Gynäkologie und Geburtshilfe Not yet recruiting Kiel, Germany Contact: Felix Hilpert, PD Dr. +49431/597-2047 fhilpert@email.uni-kiel.de Contact: Elna Kühnle, Dr. med. +49431/597-2100 elna.k@web.de Principal Investigator: Felix Hilpert, PD Dr. Sub-Investigator: Elna Kühnle, Dr. med. Universitätsklinikum Schleswig-Holstein Campus Lübeck Klinik für Frauenheilkunde und Geburtshilfe (Gynäkologie) Not yet recruiting Lübeck, Germany, 23538 Contact: Lars Hanker, Dr. med. lars.hanker@uksh.de Contact: Dörte Lüdders, Dr. med. Principal Investigator: Lars Hanker, Dr. med. Sub-Investigator: Dörte Lüdders, Dr. med. Universitätsklinikum Gießen und Marburg GmbH Klinik für Gynäkologie, gyn. Endokrinologie und Onkologie Not yet recruiting Marburg, Germany, 35043 Contact: Klaus H. Baumann, Dr. med. 496421/5866491 baumannk@med.uni-marburg.de Contact: Ellen Neubauer Principal Investigator: Klaus Baumann, Dr. med. Sub-Investigator: Ellen Neubauer, Dr. med. Universitätsfrauenklinik Tübingen Not yet recruiting Tübingen, Germany, 72076 Contact: Eva-Maria Grischke, Professor Dr. med. +497071/ 298 2212 eva-maria.grischke@med.uni-tuebingen.de Contact: Christian Wieland, Gall Principal Investigator: Eva-Maria Grischke, Prof. Dr. med. Sub-Investigator: Christian Wieland Gall, Dr. med. Universitätsklinikum Ulm Klinik für Frauenheilkunde und Geburtshilfe Not yet recruiting Ulm, Germany, 89075 Contact: Wolfgang Janni, Prof. Dr. med. +49731 500 58 500 wolfgang.janni@uniklinik-ulm.de Contact: De Gregorio Nicolaus, Dr. med. +49731/500 58688 nikolaus.de-gregorio@uniklinik-ulm.de Principal Investigator: Wolfgang Janni, Prof. Dr. med. Sub-Investigator: Nicolaus De Gregorio, Dr. med. 收起 <<
NCT02113826	Metastatic Alveolar Soft Part ... 展开 >>Sarcoma 收起 <<	Phase 2	Terminated(Low accrual rate)	-	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 收起 <<
NCT01542047	Cancer, Metastatic	Phase 1	Terminated(Low rate of accrual... 展开 >>) 收起 <<	-	United States, New Mexico ... 展开 >> University of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87131-0001 收起 <<
NCT01184326	-		Completed	-	-
NCT02729194	Carcinoma, Renal Cell	Early Phase 1	Active, not recruiting	April 2020	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT02279576	Penile Squamous Cell Carcinoma... 展开 >> Stage IV 收起 <<	Phase 2	Terminated(The low recruitment... 展开 >> of patients will not allow to complete the study with the required number of patients within reasonable time.) 收起 <<	-	Spain ... 展开 >> Institut Català D'Oncologia L'Hospitalet Hospitalet de Llobregat, Barcelona, Spain, 08908 Complejo Hospitalario de Navarra Pamplona, Navarra, Spain, 31008 Hospital de La Santa Creu I Sant Pau Barcelona, Spain, 08025 Complejo Hospitalario Regional Reina Sofía Córdoba, Spain, 14004 Hospital Universitario Lucus Augusti Lugo, Spain, 27003 Hospital Clínico San Carlos Madrid, Spain, 28040 Hospital General Universitario J.M. Morales Meseguer Murcia, Spain, 30008 Instituto Valenciano de Oncología Valencia, Spain, 46009 收起 <<
NCT01072890	Solid Tumors	Phase 1	Completed	-	United States, California ... 展开 >> University of California Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT01975519	Advanced Soft Tissue Sarcoma	Phase 1 Phase 2	Active, not recruiting	March 2020	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35243 United States, California Sarcoma Oncology Center Santa Monica, California, United States, 90403 United States, Florida Mayo Clinic Jacksonville Jacksonville, Florida, United States, 32224 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 92122 Mount Sinai School of Medicine-Tisch Cancer Institute New York, New York, United States, 10029 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Texas Mary Crowley Cancer Research Center Dallas, Texas, United States, 75230 United States, Utah University of Utah Salt Lake City, Utah, United States, 84112 收起 <<
NCT01361113	Renal Cell Carcinoma	Phase 2	Completed	-	United States, North Carolina ... 展开 >> North Carolina Cancer Hospital (UNC) Chapel Hill, North Carolina, United States, 27599 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01430572	Advanced Cancers ... 展开 >> Solid Tumors 收起 <<	Phase 1	Active, not recruiting	October 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01361113	-		Completed	-	-
NCT02055690	Ovarian Neoplasms ... 展开 >> Neoplasms, Ovarian Ovarian Cancer 收起 <<	Phase 1 Phase 2	Terminated(Safety)	-	United Kingdom ... 展开 >> Royal United Hospital Bath NHS Trust Bath, United Kingdom, BA1 3NG City Hospital Birmingham, United Kingdom, B18 7GH University Hospitals Bristol NHS Foundation Trust Bristol, United Kingdom, BS1 3NU University Collage London Hospitals NHS Foundation Trust London, United Kingdom, NW1 2PG The Royal Marsden NHS Foundation Trust London, United Kingdom, SM2 5PT The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Clatterbridge Centre for Oncology NHS Foundation Trust Merseyside, United Kingdom, CH63 4JY Mount Vernon Cancer Centre (East and North Herts NHS Trust) Middlesex, United Kingdom, HA6 2RN Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust) Newcastle-upon-Tyne And Wear, United Kingdom, NE7 7DN Oxford Radcliffe Hospitals NHS Trust Oxford, United Kingdom, OX3 9DU 收起 <<
NCT02331498	Glioblastoma Multiforme	Phase 1 Phase 2	Recruiting	December 2018	France ... 展开 >> Centre Antoine Lacassagne Recruiting Nice, Cedex 2, France, 06189 Contact: Esma SAADA BOUZID, Md +33492031618 esma.saada-bouzid@nice.unicancer.fr Contact: Christine LOVERA +33492031618 christine.lovera@nice.unicancer.fr Principal Investigator: Esma SAADA BOUZID, Dr Sub-Investigator: Jérôme BARRIERE, Pr. Sub-Investigator: Pierre Yves BONDIAU, Dr. 收起 <<
NCT01759303	Osteosarcoma ... 展开 >>Metastatic Osteosarcoma 收起 <<	Phase 2	Terminated(low accrual)	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 United States, Massachusetts Massachusetts General Hospital/Dana Farber Cancer Institute Boston, Massachusetts, United States, 02114 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03149120	Soft Tissue Sarcomas	Phase 2	Withdrawn(No patient enrolled ... 展开 >>as new similar study will be in system within 3 months) 收起 <<	June 2022	United States, New York ... 展开 >> New York University School of Medicine New York, New York, United States, 10016 收起 <<
NCT01600573	Ovarian Cancer	Phase 1 Phase 2	Unknown	March 2017	Germany ... 展开 >> Charité Campus Virchow-Klinikum Recruiting Berlin, Germany, 13353 Contact: Jalid Sehouli, Prof. Dr. +49 (0) 30 450 ext 564002 jalid.sehouli@charite.de Contact: Radoslav Chekerov, Dr. +49 (0) 30/450 ext 664399 radoslav.chekerov@charite.de Principal Investigator: Jalid Sehouli, Prof. Dr. Sub-Investigator: Radoslav Chekerov, Dr. 收起 <<
NCT01743482	Germ Cell Tumors ... 展开 >> Measurable Disease Relapse or Progression After 2 or 3 Chemotherapy Regimens. Relapse or Progression After High-dose Chemotherapy. 收起 <<	Phase 2	Unknown	April 2015	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milano, Mi, Italy, 20133 Contact: Andrea Necchi, MD +39 02 2390 2402 andrea.necchi@istitutotumori.mi.it Sub-Investigator: Patrizia Giannatempo, MD Principal Investigator: Andrea Necchi, MD 收起 <<
NCT02575066	Sarcoma Soft ... 展开 >>Tissue Sarcomas 收起 <<	Phase 2	Recruiting	April 2021	Netherlands ... 展开 >> Antoni van Leeuwenhoek Recruiting Amsterdam, Netherlands, 1066CX Contact: Rick Haas, MD, PhD +31 20 512 9111 r.haas@nki.nl Contact: Neeltje Steeghs, MD, PhD +31 20 512 9111 n.steeghs@nki.nl Leids Universitair Medisch Centrum Not yet recruiting Leiden, Netherlands, 2333 ZA Contact: A.J. Verschoor, MD +31 71 526 9111 a.j.verschoor@lumc.nl Principal Investigator: A.J. Verschoor, MD United Kingdom Royal Marsden Hospital Recruiting London, United Kingdom, SW3 6JJ Contact: Aisha Miah, MRCP, FRCR, PhD +31 44 20 7808 2591 aisha.miah@rmh.nhs.uk Principal Investigator: Aisha Miah, MRCP, FRCR, PhDMRCP, FRCR, PhD 收起 <<
NCT02193152	Carcinoma, Non-Small Cell Lung... 展开 >> Non-Small Cell Lung Cancer Nonsmall Cell Lung Cancer 收起 <<	Phase 1	Recruiting	December 31, 2018	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Daniel Morgensztern, M.D. 314-362-5737 danielmorgensztern@wustl.edu Contact: Cindy Fogal 314-362-1518 clfogal@wustl.edu Sub-Investigator: Ramaswamy Govindan, M.D. Principal Investigator: Daniel Morgensztern, M.D. Sub-Investigator: Maria Baggstrom, M.D. Sub-Investigator: Saiama Waqar, M.D. 收起 <<
NCT02303028	Solid Tumors ... 展开 >>Central Nervous System Tumors 收起 <<	Phase 1 Phase 2	Recruiting	December 2018	Canada, Alberta ... 展开 >> Alberta Children's Hospital Recruiting Calgary, Alberta, Canada Contact: Pina Giuliano Principal Investigator: Victor Lewis Canada, British Columbia BC Children's Hospital Recruiting Vancouver, British Columbia, Canada Contact: Stephanie Badour Contact: Jessica Davis Principal Investigator: Rebecca Deyell Canada, Manitoba CancerCare Manitoba Recruiting Winnipeg, Manitoba, Canada Contact: Rebekah Hiebert Contact: Kathy Hjalmarsson Principal Investigator: John Doyle Canada, Nova Scotia IWK Health Centre Recruiting Halifax, Nova Scotia, Canada Contact: Lynn Russell Principal Investigator: Jason Berman Canada, Ontario Children's Hospital of Eastern Ontario (CHEO) Recruiting Ottawa, Ontario, Canada Contact: Isabelle LaForest Principal Investigator: Donna Johnston The Hospital for Sick Children Recruiting Toronto, Ontario, Canada Contact: Gina Lee Principal Investigator: Daniel Morgenstern Canada, Quebec CHU St. Justine Hopital Recruiting Montreal, Quebec, Canada Contact: Dominique Lafreniere Principal Investigator: Monia Marzouki 收起 <<
NCT01521715	Locally Advanced and/or Metast... 展开 >>atic Renal Cell Carcinoma Carcinoma, Renal Cell Clear-cell Metastatic Renal Cell Carcinoma 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Urolog. Klinik im Waldkrankenhaus St. Marien, Friedrich-Alexander-Universität Erlangen, Germany, 91054 Universitätsklinikum Essen, Klinik f. Urologie Essen, Germany, 45122 Med. Klinik II, Johann-Wolfgang-Goethe-Universität Frankfurt, Germany, 60590 Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH Fulda, Germany, 36043 Universitätsmedizin Greifswald Greifswald, Germany, 17475 Medizinische Hochschule Hannover Hannover, Germany, 30625 Ludwig-Maximilians-Universität (LMU) München, Klinikum Grosshadern München, Germany, 81377 Universitätsklinikum Münster Münster, Germany, 48149 收起 <<
NCT01545817	Carcinoma, Renal Cell	Phase 2	Terminated(Due to changes in t... 展开 >>he RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objectives.) 收起 <<	-	Australia, Australian Capital ... 展开 >>Territory Novartis Investigative Site Garran, Australian Capital Territory, Australia, 2606 Australia, New South Wales Novartis Investigative Site Kogarah, New South Wales, Australia, 2217 Australia, Queensland Novartis Investigative Site Auchenflower, Queensland, Australia, 4066 Novartis Investigative Site Southport, Queensland, Australia, 4215 Australia, South Australia Novartis Investigative Site Elizabeth Vale, South Australia, Australia, 5112 Novartis Investigative Site Kurralta Park, South Australia, Australia, 5037 Novartis Investigative Site Woodville, South Australia, Australia, 5011 Australia, Victoria Novartis Investigative Site Footscray, Victoria, Australia, 3011 Novartis Investigative Site Frankston, Victoria, Australia, 3199 Australia, Western Australia Novartis Investigative Site Nedlands, Western Australia, Australia, 6009 Novartis Investigative Site Perth, Western Australia, Australia, 6001 Korea, Republic of Novartis Investigative Site Gyeonggi-do, Korea, Republic of, 410-769 Novartis Investigative Site Seoul, Korea, Republic of, 110-744 Novartis Investigative Site Seoul, Korea, Republic of, 135-710 Novartis Investigative Site Seoul, Korea, Republic of, 138-736 收起 <<
NCT02324803	Self Efficacy ... 展开 >> Adverse Drug Event Carcinoma, Renal Cell 收起 <<	Phase 2	Unknown	December 2015	China, Guangdong ... 展开 >> The First Affiliated Hospital of Guangzhou Medical University Recruiting Guangzhou, Guangdong, China, 510120 Contact: Mian Xie 收起 <<
NCT02979899	Advanced Angiosarcoma	Phase 3	Recruiting	December 2019	-
NCT01642017	Metastatic Cancer (Different S... 展开 >>olid Tumour Types) 收起 <<	Phase 1	Terminated(Slow recruitment ra... 展开 >>te) 收起 <<	-	France ... 展开 >> Hôpital Saint André Bordeaux, France, 33075 Centre François BACLESSE Caen, France, 14076 Centre Léon BERARD Lyon, France, 69008 Institut Claudius REGAUD Toulouse, France, 31052 收起 <<
NCT01361334	Acute Myeloid Leukemia	Phase 2	Completed	-	Germany ... 展开 >> Unviersity Hospital of Münster (UKM) Münster, Germany, 48149 收起 <<
NCT01577784	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Unknown	October 2015	Spain ... 展开 >> Hospital Universitario Central de Asturias Oviedo, Asturias, Spain, 33006 Hospital Universitari Son Espases Palma de Mallorca, Baleares, Spain, 07010 Hospital Universitari Germans Trias i Pujol Badalona, Barcelona, Spain, 08916 Hospital de Bellvitge Hospitalet de Llobregat, Barcelona, Spain, 08907 Corporació Sanitaria Parc Taulí Sabadell, Barcelona, Spain, 08208 Hospital del Mar Barcelona, Spain, 08003 Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08025 Hospital General Universitario Gregorio Marañón Madrid, Spain, 28009 Hospital 12 de Octubre Madrid, Spain, 28026 Hospital Clínico San Carlos Madrid, Spain, 28040 收起 <<
NCT02138526	Cancer	Phase 1	Recruiting	May 2018	Netherlands ... 展开 >> RadboudUMC Recruiting Nijmegen, Gelderland, Netherlands, 6500 HB 收起 <<
NCT02776644	-		Completed	-	-
NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT02795819	Renal Cell Carcinoma ... 展开 >> Soft Tissue Sarcoma Metastatic Disease 收起 <<	Phase 1	Active, not recruiting	June 30, 2025	United States, Virginia ... 展开 >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT00610012	-		Active, not recruiting	August 2020	Germany ... 展开 >> iOMEDICO Freiburg, Germany 收起 <<
NCT03419572	-		Recruiting	January 5, 2021	-
NCT01758575	-		Terminated	-	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Netherlands, 1081HV 收起 <<
NCT03387514	Renal Cell Carcinoma	Phase 2	Recruiting	January 15, 2022	United States, Wisconsin ... 展开 >> University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 53705 Contact: Cancer Connect 800-622-8922 cancerconnect@uwcarbone.wisc.edu 收起 <<
NCT02645149	Melanoma	Phase 4	Not yet recruiting	August 2021	Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies 收起 <<
NCT02788201	Urothelial Carcinoma ... 展开 >> Bladder Cancer Urinary Bladder Neoplasms 收起 <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT03413176	-		Completed	-	France ... 展开 >> AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM. Paris, France, 75013 收起 <<
NCT02747173	-		Terminated	-	Spain ... 展开 >> Hospital Universitario central de Asturias Oviedo, Asturias, Spain, 33011 Hospital de Donostia San Sebastián, Guipuzcoa, Spain, 20080 Complejo Hospitalario Univ de Santiago de Compostela Santiago de Compostela, La Coruña, Spain, 15706 Hospital de Navarra Pamplona, Navarra, Spain, 31008 Complejo Hospitalario Univ de Vigo Vigo, Pontevedra, Spain, 36204 Consorcio Hospitalario Parc Tauli Barcelona, Spain, 08208 Complejo Hospitalario de León Leon, Spain, 24071 Hospital Univ Lucus Augusti Lugo, Spain, 27003 Complejo Hospitalario de Ourense Ourense, Spain, 32005 Instituto Valenciano de Oncologia Valencia, Spain, 46009 Hospital Universitario La Fe Valencia, Spain, 46026 Hospital Miguel Servet Zaragoza, Spain, 50009 收起 <<
NCT01700699	-		Unknown	October 2013	Italy ... 展开 >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD 收起 <<
NCT01636908	Cancer Advanc... 展开 >>ed Solid Tumors 收起 <<	Not Applicable	Active, not recruiting	-	Netherlands ... 展开 >> VUMedical Center Amsterdam, Netherlands, 1081 HV 收起 <<
NCT02228954	-		Active, not recruiting	December 2019	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Netherlands University Medical Center Groningen Groningen, Netherlands Radboudumc Nijmegen, Netherlands, 6525GA 收起 <<
NCT02086695	-		Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 Canada, Manitoba St. Boniface General Hospital Winnipeg, Manitoba, Canada, R2H 2A6 收起 <<
NCT02009449	Melanoma Pros... 展开 >>tate Cancer Ovarian Cancer Renal Cell Carcinoma Colorectal Carcinoma Pancreatic Carcinoma Non-small Cell Lung Carcinoma Solid Tumors Breast Cancer 收起 <<	Phase 1	Active, not recruiting	March 2020	United States, California ... 展开 >> UCLA Medical Hematology & Oncology Los Angeles, California, United States, 90024 UCSF San Francisco, California, United States United States, Colorado Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists & Research Institute Sarasota, Florida, United States, 34232 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Oklahoma Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 South Texas Accelerated Research Therapeutics San Antonio, Texas, United States, 78229 收起 <<
NCT02044354	Metastatic Castration-resistan... 展开 >>t Prostate Cancer 收起 <<	Phase 3	Active, not recruiting	April 2018	France ... 展开 >> Gustave Roussy Villejuif, Val de Marne, France, 94805 收起 <<
NCT01793636	Metastatic Clear Cell Renal Ca... 展开 >>rcinoma 收起 <<	Phase 2	Terminated(Inferior efficacy o... 展开 >>f study drug in renal indication.) 收起 <<	November 2015	United Kingdom ... 展开 >> Royal Bournemouth Hospital Bournemouth, United Kingdom, BH7 7DW Royal Sussex County Hospital Brighton, United Kingdom, BN2 5BE University Hospitals Coventry & Warwickshire NHS Trust Coventry, United Kingdom, CV2 2DX Beatson West of Scotland Cancer Center Glasgow, United Kingdom, G12 0YN St. James' Hospital Leeds, United Kingdom, LS9 7TF Barts Health NHS Trust London, United Kingdom, EC1A 6BE Royal Free London Hospital London, United Kingdom, NW3 2QG Southampton General Hospital Southampton, United Kingdom, SO16 6YD Southend University Hospital NHS Foundation Trust Westcliff-On-Sea, United Kingdom, SS0 0RY 收起 <<
NCT01755195	Refractory Soft Tissue Sarcoma... 展开 >>s 收起 <<	Phase 2	Active, not recruiting	March 31, 2019	United States, California ... 展开 >> University of California at Davis Health System Sacramento, California, United States, 95816 City of Hope Medical Group South Pasadena, California, United States, 91030 Stanford University Stanford, California, United States, 94305-5584 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02599779	Stage IV Renal Cell Cancer AJC... 展开 >>C V7 收起 <<	Phase 2	Recruiting	March 2021	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Richard Lee-Ying, MD richard.lee-ying@albertahealthservices.ca Principal Investigator: Richard Lee-Ying, MD Canada, Ontario Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Georg A. Bjarnason, MD 416-480-5847 georg.bjarnason@sunnybrook.ca Contact: Nesan Bandali, RN 416-480-5000 ext 82139 nesan.bandali@sunnybrook.ca Principal Investigator: Georg A. Bjarnason, MD Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Aaron Hansen, MD 416-946-4501 aaron.hansen@uhn.ca Principal Investigator: Aaron Hansen, MD 收起 <<
NCT01620970	Transitional Cell Carcinoma of... 展开 >> Bladder 收起 <<	Phase 2	Unknown	October 2013	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy, 20133 收起 <<
NCT00782275	-		Completed	-	-
NCT03359018	Progression-free Survival ... 展开 >> Overall Survival Clinical Benefit Rate Toxicity 收起 <<	Phase 2	Active, not recruiting	March 1, 2020	China ... 展开 >> Musculoskeletal Tumor Center of Peking University People's Hospital Beijing, China, 100044 Peking University Shougang Hospital Beijing, China, 100144 收起 <<
NCT01900743	Sarcoma	Phase 2	Active, not recruiting	March 31, 2019	Austria ... 展开 >> Medizinische Universität Graz Graz, Austria, 8036 Universitätsklinik für Innere Medizin I Innsbruck, Austria, 6020 LKH Klagenfurt, Austria Krankenhaus der Barmherzigen Schwestern Linz Linz, Austria, 4010 AKH-Wien Wien, Austria, 1090 France Hôpital St Jacques Besancon, France, 25000 Institut Bergonié Bordeaux, France, 33076 Centre François Baclesse Caen, France, 14076 Centre GF Leclercq Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 Hôpital de La Timone Marseille, France, 13354 Centre René Gauducheau Nantes, France, 44805 Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75005 Hôpital Saint Louis Paris, France, 75010 Hôpital Cochin Paris, France, 75014 Centre Eugène Marquis Rennes, France, 35042 Centre Henri Becquerel Rouen, France, 76038 Institut Curie - Hôpital René Huguenin Saint Cloud, France, 92210 Institut de Cancérologie Lucien Neuwirth (ICL) St Priest En Jarez, France, 42270 Institut Claudius Regaud Toulouse, France, 32052 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54519 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT02086734	-		Completed	-	Germany ... 展开 >> Urologische Klinik und Poliklinik der Universität München München, Bavaria, Germany, 81377 收起 <<
NCT03456401	Renal Cancer Cell	Phase 2	Terminated(availability of new... 展开 >> and more promising therapeutic agents than expected in the experimentation in question) 收起 <<	-	Italy ... 展开 >> Istituto Tumori Milan, Mi, Italy, 20156 收起 <<
NCT02156310	-		Completed	-	Australia, South Australia ... 展开 >> Department of Clinical Pharmacology Adelaide, South Australia, Australia, 5042 收起 <<
NCT00782275	Renal Cell Carcinoma ... 展开 >> Kidney Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Tennessee Vanderbilt Univeristy Medical Center Nashville, Tennessee, United States, 37232 收起 <<
NCT01265810	Oral Complaints ... 展开 >> Renal Cell Carcinoma Hepatocellular Carcinoma Gastrointestinal Stromal Tumors 收起 <<	Phase 3	Completed	-	Netherlands ... 展开 >> The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands, 1066 CX Leiden University Medical Centre (LUMC) Leiden, Netherlands, 2300 RC 收起 <<
NCT02751827	-		Recruiting	February 2019	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO, MD,PhD Principal Investigator: Antoine ITALIANO, MD,PhD Centre Léon Bérard Not yet recruiting Lyon Cedex 08, France, 69373 Contact: Jean-Yves BLAY, MD, PhD Principal Investigator: Jean-Yves BLAY, MD, PhD 收起 <<
NCT01391962	Sarcoma, Alveolar Soft Part	Phase 2	Recruiting	December 15, 2019	United States, California ... 展开 >> Santa Monica Oncology Center Recruiting Santa Monica, California, United States, 90403 Contact: Shivaani Kummar, M.D. 301-435-5402 kummars@mail.nih.gov United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937 United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030-4096 Canada, Ontario Princess Margaret Cancer Center Recruiting Toronto, Ontario, Canada, M5G2M9 收起 <<
NCT02789137	-		Recruiting	October 30, 2018	Spain ... 展开 >> Hospital Arquitecto Marcide de Ferrol Recruiting Ferrol, A Coruña, Spain, 15405 Hospital Asil de Granollers Recruiting Granollers, Barcelona, Spain, 08402 Hospital Parc Taulí Recruiting Sabadell, Barcelona, Spain, 08208 Hospital Galdakano Recruiting Usansolo, Bizkaia, Spain, 48960 Complejo Hospitalario la Mancha Centro Recruiting Alcazar de San Juan, Ciudad REAL, Spain, 13600 Hospital Universitari Son Espases Recruiting Palma, Mallorca, Spain, 07120 H. Universitario Infanta Cristina Recruiting Badajoz, Spain, 06006 Hospital Vall de Hebrón Recruiting Barcelona, Spain, 08035 Hospital Universitario Ciudad Real Recruiting Ciudad Real, Spain, 13005 H. Reina Sofía de Cordoba Recruiting Córdoba, Spain, 14004 Hospital de Cabueñes Not yet recruiting Gijón, Spain, 33394 ICO Girona (Hospital Dr.Josep Trueta) Recruiting Girona, Spain, 17007 Hospital Universitario de Guadalajara Not yet recruiting Guadalajara, Spain, 19002 Complejo Hospitalario de Jaén Recruiting Jaén, Spain, 23007 Complejo Hospitalario de León Recruiting León, Spain, 24071 Complejo Hospitalario Ourense. Hospital Santa María Nai Recruiting Ourense, Spain, 32005 Hospital General de Asturias Not yet recruiting Oviedo, Spain, 33011 Complejo Hospitalario de Navarra Recruiting Pamplona, Spain, 31008 Hospital Universitario Canarias Not yet recruiting Santa Cruz de Tenerife, Spain, 38320 Hospital de Sant Pau i Santa Tecla Recruiting Tarragona, Spain, 43003 Hospital Virgen de la Salud Recruiting Toledo, Spain, 45071 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46011 H Clínico Zaragoza Recruiting Zaragoza, Spain, 50009 收起 <<
NCT01224288	Renal Cell Carcinoma	Phase 3	Active, not recruiting	January 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02048371	Liposarcoma O... 展开 >>steogenic Sarcoma Ewing/Ewing-like Sarcoma Rhabdomyosarcoma 收起 <<	Phase 2	Recruiting	December 2020	United States, California ... 展开 >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Torie Fechner 626-256-4673 tfechner@coh.org Principal Investigator: Warren Chow, MD Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Magnolia Manzano 323-361-8156 mmanzano@chla.usc.edu Sarcoma Oncology Research Center Recruiting Santa Monica, California, United States, 90403 Contact: Victoria Chua 310-552-9999 vchua@sarcomaoncology.com Principal Investigator: Sant Chawla, MD Stanford University Recruiting Stanford, California, United States, 94305 Contact: Maria Ahern 650-725-6413 mahern@stanford.edu Principal Investigator: Kristen Ganjoo, MD United States, Florida Mayo Clinic - Florida Recruiting Jacksonville, Florida, United States, 32224 Contact: Steven Attia, DO 904-953-7292 Attia.Steven@mayo.edu Principal Investigator: Steven Attia, DO H. Lee Moffitt Terminated Tampa, Florida, United States, 33612 United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Rasima Cehic 312-695-2082 rasima.cehic@northwestern.edu Principal Investigator: Mark Agulnik, MD United States, Indiana Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Michele Niland 317-278-0778 mniland@iupui.edu Principal Investigator: Daniel Rushing, MD United States, Massachusetts Dana Farber/Partners Cancer Care Terminated Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic - Minnesota Recruiting Rochester, Minnesota, United States, 55905 Contact: Elizabeth Smith 507-293-3817 Smith.Elizabeth6@mayo.edu Principal Investigator: Scott Okuno, MD United States, North Carolina Carolinas Healthcare System Recruiting Charlotte, North Carolina, United States, 28203 Contact: Michelle Treadwell 980-442-2332 Michelle.Treadwell@carolinashealthcare.org Principal Investigator: Michael Livingston, MD Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Colleen Piechocki 919-681-1883 colleen.piechocki@duke.edu Principal Investigator: Richard Riedel, MD United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43202 Contact: Comprehensive Cancer Center 800-293-5066 Jamesline@osumc.edu Principal Investigator: David Liebner, MD United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239 Contact: David Boody-Alter 503-418-9655 boodyalt@ohsu.edu Principal Investigator: Lara Davis, MD United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37232 Contact: Melissa Sindler 615-875-0060 melissa.m.sindler@vanderbilt.edu Principal Investigator: Vicky Keedy, MD United States, Utah Huntsman Cancer Institute Recruiting Salt Lake City, Utah, United States, 84112 Contact: Justin Parker 801-587-4702 justin.parker@hci.utah.edu Principal Investigator: Jennifer Wright, MD United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore 206-288-6425 romoore@seattlecca.org Principal Investigator: Elizabeth Loggers, MD, PhD 收起 <<
NCT02338570	Renal Cell Carcinoma	Phase 4	Terminated(Stopped on November... 展开 >> 16th 2016, because of recruitment failure.) 收起 <<	-	Italy ... 展开 >> Spedali Civili Brescia, Italy Ospedale A Perrino Brindisi, Italy Istituto Europeo di Oncologia Milano, Italy Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale Napoli, Italy AOU Maggiore della Carità Novara, Italy Casa di Cura La Maddalena Palermo, Italy Unicampus Biomedico Roma, Italy AOU San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy 收起 <<
NCT02029001	Malignant Solid Neoplasms	Phase 2	Recruiting	October 2022	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO +335 56 33 33 33 a.italiano@bordeaux.unicancer.fr Principal Investigator: Antoine ITALIANO Sub-Investigator: Delphine GARBAY Sub-Investigator: Maud TOULMONDE Sub-Investigator: Sophie COUSIN Sub-Investigator: Sylvestre LE MOULEC Sub-Investigator: Mathilde CABART Sub-Investigator: Guilhem ROUBAUD Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France, 63011 Contact: Xavier DURANDO 04 73 27 81 31 xavier.durando@cjp.fr Principal Investigator: Xavier DURANDO Sub-Investigator: Pierre DALLOZ Sub-Investigator: Anne-Françoise DILLIES-LEGRAIN Sub-Investigator: Pascale DUBRAY-LONGERAS Sub-Investigator: Hakim MAHAMMEDI Sub-Investigator: Marie-Ange MOURET-REYNIER Sub-Investigator: Isabelle VAN PRAAGH DOREAU Institut Daniel Hollard Not yet recruiting Grenoble, France, 38028 Contact: Cécile LEYRONNAS 04 76 70 73 33 c.leyronnas@ghm-grenoble.fr Principal Investigator: Cécile LEYRONNAS, MD Sub-Investigator: Claire GARNIER-TIXIDRE, MD Sub-Investigator: Laurence LANCRY-LECOMTE, MD Sub-Investigator: Jérôme LONG, MD Sub-Investigator: Christine REBISCHUNG, MD Centre Leon Berard Recruiting Lyon, France, 69373 Contact: Jean-Yves BLAY +33478785126 jean-yves.blay@lyon.unicancer.fr Principal Investigator: Jean-Yves BLAY, MD Sub-Investigator: Virginie AVRILLON Sub-Investigator: Thomas BACHELOT Sub-Investigator: Christophe BERGERON Sub-Investigator: Pierre BIRON Sub-Investigator: Helen BOYLE Sub-Investigator: Philippe CASSIER Sub-Investigator: Patrick COMBEMALE Sub-Investigator: Maria CHELGHOUM Sub-Investigator: Françoise DESSEIGNE Sub-Investigator: Cécile FAURE-CONTER Sub-Investigator: Jérome FAYETTE Sub-Investigator: Aude FLECHON Sub-Investigator: Christelle DE LA FOUCHARDIERE Sub-Investigator: Didier FRAPPAZ Sub-Investigator: Pierre GUIBERT Sub-Investigator: Pierre-Etienne HEUDEL Sub-Investigator: Eve-Marie NEIDHARDT Sub-Investigator: Maurice PEROL Sub-Investigator: Isabelle RAY-COQUARD Sub-Investigator: Paul REBATTU Sub-Investigator: Pierre SAINTIGNY Sub-Investigator: Catherine TERRET Sub-Investigator: Olivier TREDAN Sub-Investigator: Olivia BALLY Sub-Investigator: Stéphane DEPIL Sub-Investigator: Olfa DERBEL Sub-Investigator: Nathalie MARQUES Sub-Investigator: Philippe TOUSSAINT Sub-Investigator: Mehdi BRAHMI Sub-Investigator: Matthieu SARABI Sub-Investigator: Alice BONNEVILLE-LEVARD Sub-Investigator: Nadège CORRADINI Sub-Investigator: Louis DOUBLET Sub-Investigator: Armelle DUFRESNE Sub-Investigator: Lauriane EBERST Sub-Investigator: Sylvie NEGRIER Sub-Investigator: Katell MICHAUX Sub-Investigator: Anne-Sophie MICHALLET Sub-Investigator: Guillaume MAURICEAU Sub-Investigator: Juliette REURE Sub-Investigator: Pauline ROCHEFORT Hopital Edouard Herriot Not yet recruiting Lyon, France, 69437 Contact: Julien FORESTIER, MD +33472119738 julien.forestier@chu-lyon.fr Principal Investigator: Julien FORESTIER Sub-Investigator: Catherine LOMBARD BOHAS Sub-Investigator: Thomas WALTER Sub-Investigator: Yann MOLIN Sub-Investigator: Noura BEN SLAMA Institut Paoli Calmettes Recruiting Marseille, France, 13273 Contact: François BERTUCCI +334 91 22 35 37 bertuccif@ipc.unicancer.fr Principal Investigator: François BERTUCCI Sub-Investigator: Jean-Marc EXTRA Sub-Investigator: Anthony GONCALVES Sub-Investigator: Gwenaêlle GRAVIS-MESCAM Sub-Investigator: Anne MADROSZYK-FLANDIN Sub-Investigator: Jean-Luc RAOUL Sub-Investigator: Delphine PERROT Sub-Investigator: Magali PROVENSAL Sub-Investigator: Carole TARPIN Sub-Investigator: Frédéric VIRET Sub-Investigator: Louis TASSY Sub-Investigator: Maria Antonietta CAPPIELLO Sub-Investigator: Slimane DERMECHE Sub-Investigator: Simon LAUNAY Sub-Investigator: Frederique ROUSSEAU Sub-Investigator: Nicolas MEYER Sub-Investigator: Loïc MOUREY Sub-Investigator: Elisabeth MOYAL Sub-Investigator: Roxana Maria RADUT Sub-Investigator: Henri ROCHE Sub-Investigator: Thibaud VALENTIN Sub-Investigator: Sarah ZAHI Institut Curie Recruiting Paris, France, 75248 Contact: Christophe LE TOURNEAU, MD +33144324672 Christophe.letourneau@curie.fr Principal Investigator: Christophe LE TOURNEAU, MD Sub-Investigator: Philippe BEUZEBOC Sub-Investigator: François-Clément BIDARD Sub-Investigator: Bruno BUECHER Sub-Investigator: Paul-Henri COTTU Sub-Investigator: Catherine DANIEL Sub-Investigator: Véronique DIERAS Sub-Investigator: Valérie LAURENCE Sub-Investigator: Alain LIVARTOWSKI Sub-Investigator: Jean-Yves PIERGA Sub-Investigator: Marie ALT Sub-Investigator: Delphine LOIRAT Sub-Investigator: Marie-Paule SABLIN Sub-Investigator: Mustapha ZOUBIR Sub-Investigator: Francesco RICCI Sub-Investigator: Emanuela ROMANO Sub-Investigator: Olivier COLLARD Centre Hospitalier Lyon Sud Recruiting Pierre-Bénite, France, 69495 Contact: Benoit YOU, MD +33478864319 benoit.you@chu-lyon.fr Principal Investigator: Benoit YOU, MD Sub-Investigator: Nathalie BONNIN Sub-Investigator: Gilles FREYER Sub-Investigator: Salima HAMIZI Sub-Investigator: Sophie TARTAS Sub-Investigator: Véronique TRILLET-LENOIR Sub-Investigator: Marion CHAUVENET Sub-Investigator: Denis MAILLET Sub-Investigator: Julien PERON Sub-Investigator: Claire FALANDRY Sub-Investigator: Olivia LE SAUX Institut de cancérologie LUCIEN NEUWIRTH Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Olivier COLLARD, MD 04 77 91 70 34 olivier.collard@icloire.fr Principal Investigator: Olivier COLLARD, MD Sub-Investigator: Claire BOSACKI, MD Sub-Investigator: Pierre FOURNEL, MD Sub-Investigator: Aline GUILLOT, MD Sub-Investigator: Jean-Philippe JACQUIN, MD Sub-Investigator: Thierry MURON, MD Sub-Investigator: Léa SABAN-ROCHE, MD Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Carlos-Alberto GOMEZ-ROCA 05 31 15 51 01 Gomez-roca.carlos@iuct-oncopole.fr Principal Investigator: Carlos-Alberto GOMEZ-ROCA Sub-Investigator: Christine CHEVREAU Sub-Investigator: Ewa-Anna COTTURA Sub-Investigator: Florence DALENC Sub-Investigator: Jean-Pierre DELORD Sub-Investigator: Marion DESLANDRES Sub-Investigator: Cécile GANDY Sub-Investigator: Laurence GLADIEFF Sub-Investigator: Eleonora MAIO D'ESPOSITO Sub-Investigator: Nicolas MEYER Sub-Investigator: Loïc MOUREY Sub-Investigator: Elisabeth MOYAL Sub-Investigator: Henri ROCHE Sub-Investigator: Thibaud VALENTIN Sub-Investigator: Sarah ZAHI Sub-Investigator: Roxana Maria RADUT 收起 <<
NCT01649180	Renal Cell Carcinoma	Phase 2	Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	United States, Nebraska ... 展开 >> Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, Ohio Cleveland Clinic, Taussig Cancer Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01649180	-		Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	-
NCT02071719	-		Terminated	October 2017	Netherlands ... 展开 >> VU Medical Center Amsterdam, Noord Holland, Netherlands, 1081 HV 收起 <<
NCT02638428	Relapsed Pediatric Solid Tumor... 展开 >> Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML 收起 <<	Phase 2	Recruiting	December 2023	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung 82-2-3410-3529 kwsped@skku.edu Principal Investigator: Ki Woong Sung 收起 <<
NCT02956798	Oligometastatic Renal Cell Car... 展开 >>cinoma 收起 <<	Phase 2	Recruiting	December 31, 2021	United States, Texas ... 展开 >> University of Texas Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: Raquibul Hannan, MD 214-645-7696 Raquibul.Hannan@UTSouthwestern.edu Contact: Mehreen Aslam 214-648-8038 Mehreen.Aslam@UTSouthwestern.edu Principal Investigator: Raquibul Hannan, MD, PhD 收起 <<
NCT03185039	Kidney Cancer	Not Applicable	Recruiting	November 29, 2020	France ... 展开 >> Institut Paoli Calmettes Recruiting Marseille, France, 13009 Contact: GENRE Dominique, MD 33 (0)4 91 22 37 78 drci.up@ipc.unicancer.fr Contact: Isabelle Boquet, PhD 33 (0)4 91 22 37 78 drci.up@ipc.unicancer.fr Principal Investigator: GRAVIS Gwénaëlle, MD 收起 <<
NCT00666081	Cancer	Phase 1	Withdrawn(Study Cancelled befo... 展开 >>re enrollment) 收起 <<	December 2009	-
NCT02560012	Carcinoma, Renal Cell	Phase 2	Terminated(Loss of laboratory ... 展开 >>performing molecular analysis) 收起 <<	-	United States, Texas ... 展开 >> UTHealth Memorial Hermann Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02354612	Solid Tumors	Phase 1 Phase 2	Enrolling by invitation	December 2021	United States, California ... 展开 >> UCLA Santa Monica, California, United States, 90404 收起 <<
NCT02700568	Carcinoma, Renal Cell ... 展开 >> Clear Cell Renal Cell Carcinoma 收起 <<	Phase 2	Recruiting	August 2018	Russian Federation ... 展开 >> Demchenkova Marina Viktorovna Recruiting Irkutsk, Russian Federation Semenov Andrey Vladimirovich Recruiting Ivanovo, Russian Federation Mikhailova Nadezhda Vasilievna Recruiting Kazan, Russian Federation Eskerov Kurban Abdulmutalibovich Active, not recruiting Kirov, Russian Federation Zukov Ruslan Aleksandrovich Recruiting Krasnoyarsk, Russian Federation Ovchinnikova Elena Georgievna Recruiting Nizhny Novgorod, Russian Federation Guseva Irina Vasilievna Recruiting Penza, Russian Federation Vladimirova Lyubov Yur'evna Active, not recruiting Rostov-on-Don, Russian Federation Zolotoreva Tatiana Gennadievna Recruiting Samara, Russian Federation Katkov Alexey Aleksandrovich Active, not recruiting Saratov, Russian Federation Ivannikov Andrey Andreyevich Recruiting Tambov, Russian Federation Usynin Evgeny Anatolievich Recruiting Tomsk, Russian Federation Evstegneyeva Irina Vladimirovna Recruiting Tver, Russian Federation Khmelevsky Andrey Anatolievich Recruiting Ufa, Russian Federation Gurina Ludmila Ivanovna Active, not recruiting Vladivostok, Russian Federation 收起 <<
NCT01731158	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Unknown	May 2016	Germany ... 展开 >> Charité Berlin Berlin, Germany University Hospital Bonn Bonn, Germany University Hospital Dresden Dresden, Germany University Hospital Düsseldorf Düsseldorf, Germany Waldkrankenhaus St. Marien Erlangen, Germany University Hospital Essen Essen, Germany University Hospital Frankfurt Frankfurt, Germany University Hospital Freiburg Freiburg, Germany University Hospital Göttingen Göttingen, Germany Oncological Practice Hannover Hannover, Germany University Hospital Hannover Hannover, Germany University Hospital Magdeburg Magdeburg, Germany University Hospital Tübingen Tübingen, Germany 收起 <<
NCT02184416	-		Recruiting	July 20, 2019	-
NCT02560012	-		Terminated(Loss of laboratory ... 展开 >>performing molecular analysis) 收起 <<	-	-
NCT02049905	Metastatic, Locally Advanced o... 展开 >>r Unresectable Soft Tissue Sarcoma 收起 <<	Phase 3	Completed	-	-
NCT02960906	Clear Cell Metastatic Renal Ce... 展开 >>ll Carcinoma 收起 <<	Phase 2	Recruiting	May 2020	France ... 展开 >> Hôpital Saint André, CHU de Bordeaux Recruiting Bordeaux, France, 33075 Contact: Marine GROSS-GOUPIL, MD marine.gross-goupil@chu-bordeaux.fr Centre Francois Baclesse Recruiting Caen, France, 14000 Contact: Florence JOLY, MD,PHD f.joly@baclesse.unicancer.fr CHU Henri-Mondor Recruiting Creteil, France, 94000 Contact: Christophe TOURNIGAND, MD, PHD christophe.tournigand@aphp.fr CHD Vendée Not yet recruiting La Roche-sur-Yon, France, 85925 Contact: Franck PRIOU, MD frank.priou@chd-vendee.fr Centre OSCAR LAMBRET LILLE Recruiting Lille, France, 59000 Contact: Yaovi Messan AMELA, MD e-amela@o-lambret.fr Hôpital Européen Marseille Not yet recruiting Marseille, France, 13003 Contact: Philippe DALIVOUST philippe.dalivoust@gmail.com Institut Paoli Calmettes (IPC) Recruiting Marseille, France, 13009 Contact: Gwenaëlle GRAVIS, MD gravisg@ipc.unicancer.fr Centre Antoine Lacassagne Recruiting Nice, France, 06100 Contact: Delphine BORCHIELLINI, MD Delphine.BORCHIELLINI@nice.unicancer.fr Institut de Cancérologie du Gard - CHU Caremeau Recruiting Nîmes, France, 30029 Contact: Nadine HOUEDE, MD,PHD HOUEDE nadine Hôpital Pitié-Salpêtrière Withdrawn Paris, France, 75013 Institut Mutualiste Montsouris Recruiting Paris, France, 75014 Contact: Mostefa BENNAMOUN, MD Mostefa.Bennamoun@imm.fr Hôpital Européen Georges Pompidou Recruiting Paris, France, 75015 Contact: Yann-Alexandre VANO, MD yann.vano@aphp.fr Hôpital de la Croix Saint-Simon Not yet recruiting Paris, France, 75020 Contact: Jacques MEDIONI JMedioni@hopital-dcss.org Hôpital Cochin Recruiting Paris, France, 75679 Contact: Olivier HUILLARD, MD olivier.huillard@aphp.fr Centre Hospitalier Lyon Sud - Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL) Not yet recruiting Pierre Bénite, France, 69310 Contact: Denis MAILLET, MD denis.maillet@chu-lyon.fr Centre Eugene Marquis Recruiting Rennes, France, 35042 Contact: Brigitte LAGUERRE, MD b.laguerre@rennes.unicancer.fr Centre René Gauducheau ICO institut de Cancerologie de l'Ouest Not yet recruiting Saint-Herblain, France, 44805 Contact: Frédéric ROLLAND, MD Frederic.Rolland@ico.unicancer.fr Hôpitaux universitaires de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Philippe BARTHELEMY, MD philippe.barthelemy@chru-strasbourg.fr Hopital Foch Not yet recruiting Suresnes, France, 92151 Contact: Philippe BEUZEBOC beuzeboc.philippe@gmail.com Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Christine CHEVREAU, MD Chevreau.Christine@iuct-oncopole.fr CHU Bretonneau Recruiting Tours, France, 37000 Contact: Claude LINASSIER, MD claude.linassier@univ-tours.fr Institut Gustave Roussy Not yet recruiting Villejuif, France, 94805 Contact: Laurence ALBIGES, MD Laurence.ALBIGES@gustaveroussy.fr 收起 <<
NCT00749320	Renal Cell Carcinoma	Not Applicable	Active, not recruiting	February 2019	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02187302	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Completed	-	-
NCT03379012	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Recruiting	July 30, 2019	Russian Federation ... 展开 >> A.I. Kryzhanovsky Krasnoyarsk Cancer Center Recruiting Krasnoyarsk, Russian Federation Contact: Ruslan Zukov kidneycancer@yandex.ru Kidney Cancer Research Bureau Recruiting Moscow, Russian Federation Contact: Ilya Tsimafeyeu kidneycancer@yandex.ru RUDN University Recruiting Moscow, Russian Federation Contact: Yuliya Tishova kidneycancer@yandex.ru City Clinical Oncology Center Recruiting Saint Petersburg, Russian Federation Contact: Pavel Borisov kidneycancer@yandex.ru 收起 <<
NCT03062410	Renal Carcinoma Metastatic ... 展开 >> Kidney Neoplasms Renal Cancer 收起 <<	Not Applicable	Recruiting	February 4, 2020	France ... 展开 >> CHU de Besançon Active, not recruiting Besançon, France, 25030 Hôpital privé Sainte Marie Recruiting Chalon-sur-Saône, France, 71100 Contact: Erika Viel, MD 0033385488989 Centre de lutte contre le cancer Georges François Leclerc Recruiting Dijon, France, 21000 Contact: Sylvain Ladoire, MD 0033380737506 sladoire@cgfl.fr Hôpital Nord Franche-Comté Recruiting Montbéliard, France, 25200 Contact: Guillaume Mouillet, MD mouillet.guillaume@gmail.com Centre de lutte contre le cancer Jean Godinot Recruiting Reims, France, 51100 Contact: Jean-Christophe Eymard, MD Groupe hospitaliser St-Vincent Recruiting Strasbourg, France, 67000 Contact: Louis-Marie Dourthe, MD lm.dourthe@solcrr.org Hôpitaux Universitaires de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Philippe Barthelemy, MD philippe.barthelemy@chru-strasbourg.fr Centre de lutte contre le cancer Alexis Vautrin - Institut de Cancérologie de Lorraine Recruiting Vandœuvre-lès-Nancy, France, 54519 Contact: Lionnel Geoffrois, MD l.geoffrois@nancy.unicancer.fr 收起 <<
NCT01582204	Renal Cancer	Not Applicable	Active, not recruiting	April 2019	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT01217931	Kidney Cancer	Phase 2	Active, not recruiting	January 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01594203	-		Unknown	May 2013	Israel ... 展开 >> Hadassah Hebrew University Medical Center Not yet recruiting Jerusalem, Israel Contact: Marina Orevi, MD marinaor@hadassah.org.il Contact: Daniela Katz, MD DanielaKatz@hadassah.org.il 收起 <<
NCT03275558	Recurrent Glioblastoma ... 展开 >> Gliosarcoma Anaplastic Gliomas 收起 <<	Phase 1	Withdrawn(Study halted prior t... 展开 >>o enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision)) 收起 <<	-	Hong Kong ... 展开 >> The Hong Kong Cancer Institute Hong Kong, Hong Kong, 518031 Singapore National University Cancer Institute, Singapore, Singapore, 119074 收起 <<
NCT03571438	Kidney Cancer	Not Applicable	Recruiting	September 30, 2024	France ... 展开 >> Grenoble Alps Hospital Recruiting Grenoble, France, 38043 Contact: Jean-Luc Descotes, PU-PH 收起 <<
NCT02208128	Renal Cell Carcinoma	Not Applicable	Unknown	February 2018	Germany ... 展开 >> Urological Department of the University Hospital Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Sascha Pahernik, PD Dr. +49 6221 56 39689 sascha.pahernik@med.uni-heidelberg.de Principal Investigator: Sascha Pahernik, PD Dr. 收起 <<
NCT02406521	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02959554	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Active, not recruiting	December 2021	Austria ... 展开 >> Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie Wien, Austria, 1090 Germany Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie Essen, Germany, 45147 收起 <<
NCT01202032	Metastatic Renal Cell Carcinom... 展开 >>a Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed 收起 <<	Phase 1	Completed	-	France ... 展开 >> Centre Léon BERARD Lyon, France, 69373 收起 <<
NCT02535351	Clear-cell Metastatic Renal Ce... 展开 >>ll Carcinoma 收起 <<	Phase 3	Terminated(low enrolment)	-	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale Tumori Milan, Mi, Italy, 20133 收起 <<
NCT03519542	-		Active, not recruiting	June 2018	Spain ... 展开 >> Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, A Coruña, Spain, 15706 Hospital Universitario central de Asturias Oviedo, Asturias, Spain, 33011 Hospital Marqués de Valdecilla Santander, Cantabria, Spain, 39008 Hospital Universitarios de Burgos Burgos, Spain, 09006 Hospital Universiario de León León, Spain, 24080 Hospital Gregorio Marañón Madrid, Spain, 28007 Hospital Universitario Ramón y Cajal Madrid, Spain, 28024 Hospital Clínico (Madrid) Madrid, Spain, 28040 Hospital 12 de Octubre Madrid, Spain, 28041 Hospital Universitario La Paz Madrid, Spain Hospital Universitario Carlos Haya Málaga, Spain, 29010 Hospital Clínico Lozano Blesa Zaragoza, Spain, 50009 收起 <<
NCT00060151	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Ohio Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 收起 <<
NCT01716546	Gastric Cancer	Phase 1 Phase 2	Terminated(Not reached the pri... 展开 >>mary endpoint target according to the statistical design) 收起 <<	-	Greece ... 展开 >> "IASO" General Hospital of Athens Athens, Greece 401 Military Hospital of Athens Athens, Greece Air Forces Military Hospital of Athens Athens, Greece "Ag.Georgios" General Hospital of Chania Chania, Greece University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece Heraklion, Greece State General Hospital of Larissa Larissa, Greece "Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology Piraeus, Greece "Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology Thessaloniki, Greece Diabalkaniko General Hospital of Thessaloniki Thessaloniki, Greece 收起 <<
NCT01381614	-		Completed	-	-
NCT01514448	Metastatic Renal Cell Carcinom... 展开 >>a (mRCC) 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Novartis Investigative Site Chemnitz, Germany, 09130 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Hannover, Germany, 30559 Novartis Investigative Site Hof, Germany, 95028 Novartis Investigative Site Kassel, Germany, 34125 Novartis Investigative Site Langen, Germany, 63225 Novartis Investigative Site Leipzig, Germany, 04357 Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Muenster, Germany, 48149 Novartis Investigative Site Ravensburg, Germany, 88214 Novartis Investigative Site Velbert, Germany, 42551 Novartis Investigative Site Wiesbaden, Germany, 65191 Novartis Investigative Site Wolfsburg, Germany, 38440 收起 <<
NCT03260894	Renal Cell Carcinoma (RCC)	Phase 3	Active, not recruiting	June 2020	-
NCT01381601	-		Completed	-	-
NCT00158782	Carcinoma, Renal Cell	Phase 1	Completed	-	United States, North Carolina ... 展开 >> GSK Investigational Site Durham, North Carolina, United States, 27705 Netherlands GSK Investigational Site Rotterdam, Netherlands, 3075 EA 收起 <<
NCT01664182	Stage III Renal Cell Cancer AJ... 展开 >>CC v7 Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 2	Active, not recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States, 55416 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia VCU Massey Cancer Center at Hanover Medical Park Mechanicsville, Virginia, United States, 23116 收起 <<
NCT01408004	Clear Cell Renal Carcinoma	Phase 2	Completed	-	Netherlands ... 展开 >> St. Franciscus Gasthuis Rotterdam, Zuid-Holland, Netherlands Medisch Centrum Alkmaar Alkmaar, Netherlands Acedemisch Medisch Centrum Amsterdam Amsterdam, Netherlands NKI-AVL Amsterdam, Netherlands Amphia ziekenhuis Breda Breda, Netherlands Haga Ziekenhuis Den Haag, Netherlands Maxima Medisch Centrum Eindhoven, Netherlands UMC Groningen Groningen, Netherlands Atrium Medisch Centrum Heerlen Heerlen, Netherlands Medische Centrum Leeuwarden Leeuwarden, Netherlands Acedemisch ziekenhuis Maastricht Maastricht, Netherlands St. Antonius ziekenhuis Nieuwegein, Netherlands Erasmus Medisch Centrum Rotterdam, Netherlands Orbis Medisch Centrum Sittard-Geleen, Netherlands St. Elisabeth ziekenhuis Tilburg, Netherlands UMC Utrecht Utrecht, Netherlands, 3508 GA Isala klinieken Zwolle, Netherlands 收起 <<
NCT01208064	Lung Cancer	Phase 2 Phase 3	Terminated(based on IDMC decis... 展开 >>ion) 收起 <<	-	Belgium ... 展开 >> Universitair Ziekenhuis Gent Gent, Belgium Centre Hospitalier Regional De La Citadelle Liege, Belgium Clinique et Maternité Sainte Elisabeth Namur, Belgium Egypt National Cancer Institute Cairo, Egypt France Centre Georges-Francois-Leclerc Dijon, France Assistance Publique - Hôpitaux de Marseille - Assistance Publique - Hôpitaux de Marseille - Hopital Nord Marseille, France Germany Klinik Loewenstein Loewenstein, Germany UniversitaetsMedizin Mannheim Mannheim, Germany Greece University General Hospital Heraklion Heraklion, Greece Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam, Netherlands Amphia Ziekenhuis Breda, Netherlands Isala Klinieken Zwolle, Netherlands Slovenia University Clinic Golnik Golnik, Slovenia United Kingdom Royal Marsden - Surrey Sutton, England, United Kingdom, SM2 5PT Western General Hospital Edinburgh, United Kingdom Guy's and St Thomas' NHS London, United Kingdom Royal Marsden Hospital London, United Kingdom Christie NHS Foundation Trust Manchester, United Kingdom Nottingham University Hospitals NHS Trust Nottingham, United Kingdom Weston Park Hospital Sheffield, United Kingdom King's Mill Hospital Sutton-in-Ashfield, United Kingdom Royal Marsden Hospital Sutton, United Kingdom 收起 <<
NCT00347919	Neoplasms, Breast	Phase 2	Completed	-	-
NCT00733304	Macular Degeneration	Phase 2	Completed	-	United States, California ... 展开 >> GSK Investigational Site Beverly Hills, California, United States, 90211 GSK Investigational Site Sacramento, California, United States, 95841 United States, Florida GSK Investigational Site Winter Haven, Florida, United States, 33880 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46280 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02111 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48105 GSK Investigational Site Grand Rapids, Michigan, United States, 49525 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84132 Australia, New South Wales GSK Investigational Site Sydney, New South Wales, Australia, 2145 GSK Investigational Site Sydney, New South Wales, Australia, 2150 Australia, Victoria GSK Investigational Site Melbourne, Victoria, Australia Australia, Western Australia GSK Investigational Site Perth, Western Australia, Australia, 6009 Italy GSK Investigational Site Milano, Lombardia, Italy, 20132 GSK Investigational Site Milano, Lombardia, Italy, 20157 GSK Investigational Site Torino, Piemonte, Italy, 10122 GSK Investigational Site Firenze, Toscana, Italy, 50134 GSK Investigational Site Padova, Veneto, Italy, 35128 收起 <<
NCT00347919	-		Completed	-	-
NCT01861951	Soft Tissue Sarcoma	Phase 2	Completed	-	Belgium ... 展开 >> University Hospitals Leuven, Leuven Cancer Institute, Dept. of General Medical Oncology Leuven, Flemish Brabant, Belgium, 3000 Germany Heidelberg University Hospital, Department of Internal Medicine, Hematology, Oncology and Rheumatology Heidelberg, Baden-Wuerttemberg, Germany, 69120 University Medical Centre Mannheim, Surgical oncology Mannheim, Baden-Wuerttemberg, Germany, 68167 Medical University Tuebingen, Center for Soft Tissue Sarcoma, GIST and Bone Tumors Tuebingen, Baden-Wuerttemberg, Germany, 72076 LMU University hospital Munich Grosshadern, Medical Dept. III Munich, Bavaria, Germany, 81377 Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hanover, Lower Saxony, Germany, 30625 University Hospital RWTH Aachen, Medical Dept. IV Aachen, North Rhine-Westphalia, Germany, 52074 University Hospital Cologne Cologne, North Rhine-Westphalia, Germany, 50937 University Hospital Essen, West-German Tumor Center Essen, North Rhine-Westphalia, Germany, 45122 University Hospital Carl Gustav Carus, Internal Medicine Dept. I Dresden, Saxony, Germany, 01307 Charité Hospital, Medical Department, Division of Hematology, Oncology and Tumor Immunology Berlin, Germany, 13353 收起 <<
NCT00788580	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Withdrawn(Study was discontinu... 展开 >>ed.) 收起 <<	-	-
NCT01031875	Bladder Cancer ... 展开 >> Transitional Cell Cancer of the Renal Pelvis and Ureter Urethral Cancer 收起 <<	Phase 2	Completed	-	Italy ... 展开 >> Fondazione Istituto Nazionale dei Tumori Milan, Italy, 20133 收起 <<
NCT00733304	-		Completed	-	-
NCT00358384	Psoriasis	Phase 1	Completed	-	France ... 展开 >> GSK Investigational Site Paris, France, 75015 收起 <<
NCT00561795	Primary Peritoneal Carcinoma ... 展开 >> Tumor Epithelial Ovarian Cancer Uterine Disease Cervix Diseases Neoplasms, Ovarian Cancer 收起 <<	Phase 2	Completed	-	France ... 展开 >> GSK Investigational Site Lyon Cedex 08, France, 69373 GSK Investigational Site Strasbourg, France, 67085 Germany GSK Investigational Site Marburg, Hessen, Germany, 35043 GSK Investigational Site Wiesbaden, Hessen, Germany, 65199 GSK Investigational Site Essen, Nordrhein-westfalen, Germany, 45122 收起 <<
NCT01051700	Macular Degeneration	Phase 1	Completed	-	United States, Minnesota ... 展开 >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 United States, Texas GSK Investigational Site Austin, Texas, United States, 78744 United States, Washington GSK Investigational Site Tacoma, Washington, United States, 98418 收起 <<
NCT01961583	Kidney Neoplasm	Phase 2	Terminated(Termination of [18F... 展开 >>]Fluciclatide production) 收起 <<	April 2016	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Songpa-gu, Korea, Republic of, 138-736 收起 <<
NCT00615524	Hormone-receptor Positive Brea... 展开 >>st Cancer 收起 <<	Phase 2	Withdrawn(Cancelled Before Enr... 展开 >>ollment) 收起 <<	November 2012	United States, California ... 展开 >> GSK Clinical Trials Call Center San Francisco, California, United States, 94115 收起 <<
NCT01514448	-		Completed	-	-
NCT02570789	Clear-cell Metastatic Renal Ce... 展开 >>ll Carcinoma 收起 <<	Phase 4	Active, not recruiting	December 2018	Belgium ... 展开 >> Cliniques universitaires Saint-Luc Brussel, Belgium, 1200 收起 <<
NCT00561795	-		Completed	-	-
NCT00540943	Neoplasms, Colorectal	Phase 1	Completed	-	France ... 展开 >> GSK Investigational Site Saint Herblain, France, 44805 GSK Investigational Site Toulouse, France, 31052 收起 <<
NCT03091465	-		Completed	-	-
NCT01134055	-		Completed	-	-
NCT00388076	Neoplasms, Breast	Phase 1	Completed	-	United States, New Jersey ... 展开 >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44106 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 收起 <<
NCT01134055	Macular Degeneration	Phase 2	Completed	-	-
NCT00775307	Carcinoma, Non-Small-Cell Lung	Phase 2 Phase 3	Completed	-	France ... 展开 >> Annemasse - CH Ambilly, France, 74100 Bobigny - Hôpital Avicenne Bobigny, France, 93000 Bordeaux - Polyclinique Nord Bordeaux, France, 33300 Boulogne - Ambroise Paré Boulogne, France Béziers - CH Béziers, France, 34525 Caen - Centre François Baclesse Caen, France, 14000 Caen - CHU Côte de Nacre Caen, France, 14000 Clamart - Hôpital Percy Clamart, France, 92140 Clermont Ferrand - CHU Clermont Ferrand, France, 63000 Colmar - CH Colmar, France, 68000 Dax - CH Dax, France, 40107 Grenoble - CHU Grenoble, France, 38000 Le Mans - Centre Hospitalier Le Mans, France, 72000 Lille - Hôpital Calmette Lille, France, 59000 Mantes La Jolie - CH Mantes La Jolie, France, 78200 Marseille - Hôpital Sainte Marguerite Marseille, France, 13000 Metz - Clinique Claude Bernard Metz, France, 57000 Mont de Marsan - CH Mont de Marsan, France, 40000 Montpellier - Clinique Clémentville Montpellier, France, 34070 Montpellier - CHRU Montpellier, France, 34295 Moulins - CH Moulins, France, 03000 Nantes - Centre René Gauducheau Nantes, France, 44805 Nevers - CH Nevers, France, 58033 CHU Nîmes, France Orléans - CH Orléans, France, 45000 Paris - Saint Louis Paris, France, 75000 Paris - hôpital Saint-Antoine Paris, France, 75012 Paris - Hopital Tenon Paris, France, 75020 Pau - CH Pau, France, 64046 Centre Catalan d'Onologie Perpignan, France, 66000 Lyon Sud Pierre Bénite, France, 69495 Reims - CHU Reims, France, 51092 Rennes - CHU Rennes, France, 35033 Strasbourg - NHC Strasbourg, France, 63000 Thonon les bains - CH Thonon les bains, France, 74200 Toulon - HIA Toulon, France, 83000 Toulouse - CHU Larrey Toulouse, France Nancy - CHU Vandoeuvre lès Nancy, France, 54500 Vesoul - CHI Vesoul, France, 70000 Villejuif - Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT00678977	Lung Cancer, Non-Small Cell	Phase 1	Completed	-	Germany ... 展开 >> GSK Investigational Site Essen, Nordrhein-Westfalen, Germany, 45122 United Kingdom GSK Investigational Site Newcastle Upon Tyne, Northumberland, United Kingdom, NE4 6BE 收起 <<
NCT01362348	Macular Degeneration	Phase 2	Terminated(Lack of efficacy id... 展开 >>entified during a preliminary analysis) 收起 <<	-	United States, Arizona ... 展开 >> GSK Investigational Site Phoenix, Arizona, United States, 85014 United States, Florida GSK Investigational Site Miami, Florida, United States, 33143 GSK Investigational Site Winter Haven, Florida, United States, 33880 United States, Georgia GSK Investigational Site Decatur, Georgia, United States, 30030 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02114 United States, Michigan GSK Investigational Site Grand Rapids, Michigan, United States, 49525 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44195 United States, Texas GSK Investigational Site Austin, Texas, United States, 78705 GSK Investigational Site Houston, Texas, United States, 77030 France GSK Investigational Site Paris cedex 10, France, 75475 GSK Investigational Site Paris cedex 12, France, 75571 Germany GSK Investigational Site Muenchen, Bayern, Germany, 80336 GSK Investigational Site Bonn, Nordrhein-Westfalen, Germany, 53127 GSK Investigational Site Muenster, Nordrhein-Westfalen, Germany, 48145 GSK Investigational Site Leipzig, Sachsen, Germany, 04103 收起 <<
NCT00256880	Carcinoma, Renal Cell	Phase 2	Completed	-	United States, Arkansas ... 展开 >> GSK Investigational Site Little Rock, Arkansas, United States, 72205 United States, Massachusetts GSK Investigational Site Boston, Massachusetts, United States, 02115 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104 United States, Washington GSK Investigational Site Seattle, Washington, United States, 98109 Australia, Victoria GSK Investigational Site East Melbourne, Victoria, Australia, 3002 GSK Investigational Site Melbourne, Victoria, Australia, 3004 GSK Investigational Site Melbourne, Victoria, Australia, 3050 收起 <<
NCT01362348	-		Terminated(Lack of efficacy id... 展开 >>entified during a preliminary analysis) 收起 <<	-	-
NCT01512186	-		Unknown	December 2014	United Kingdom ... 展开 >> Basildon and Thurrock University Hospitals NHS Foundation Trust Basildon, United Kingdom University Hospitals Coventry & Warwickshire NHS Trust Coventry, United Kingdom The Beatson West of Scotland Cancer Centre Glasgow, United Kingdom Barts and London Hospital NHS Trust London, United Kingdom Oncology & Clinical Haematology Trials Unit, Royal Free Hospital London, United Kingdom Oncology & Haematology Clinical Trials Unit, Guy's Hospital London, United Kingdom Department of Oncology Oxford Cancer Centre Oxford, United Kingdom Southampton General Hospital Southampton, United Kingdom Southend University Hospital Trust Southend, United Kingdom 收起 <<
NCT00463320	Macular Degeneration ... 展开 >> Age-related Macular Degeneration 收起 <<	Phase 1	Completed	-	United States, North Dakota ... 展开 >> GSK Investigational Site Fargo, North Dakota, United States, 58104 United States, Texas GSK Investigational Site Austin, Texas, United States, 78744 收起 <<
NCT00992121	Carcinoma, Renal Cell	Phase 1	Completed	-	United Kingdom ... 展开 >> GSK Investigational Site Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ 收起 <<
NCT03139331	Sarcoma	Phase 1	Recruiting	November 30, 2019	United States, California ... 展开 >> UCSF Benioff Children's Hospital, Oakland Recruiting Oakland, California, United States, 94609 Contact: Jennifer Michlitsch, MD 510-428-3372 jmichlitsch@mail.cho.org Principal Investigator: Jennifer Michlitsch, MD UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94158 Contact: Kieuhoa Vo, MD, MAS 415-476-3831 kieuhoa.vo@ucsf.edu Principal Investigator: Kieuhoa Vo, MD, MAS United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Steven DuBois, MD 617-632-5640 steve_dubois@dfci.harvard.edu Principal Investigator: Steven DuBois, MD 收起 <<
NCT01666418	Melanoma	Phase 2	Completed	-	Switzerland ... 展开 >> University Hospital Zurich, Division of Dermatology Zurich, Switzerland 收起 <<
NCT00459862	-		Completed	-	-
NCT01931098	Glioblastoma ... 展开 >>Glioblastoma Multiforme Gliosarcoma Brain Neoplasms Central Nervous System Neoplasms 收起 <<	Phase 2	Active, not recruiting	September 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01221506	Carcinoma, Renal Cell	Early Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01644825	Ovarian Cancer	Phase 2	Completed	-	Italy ... 展开 >> Osp. Regionale Mulli Acquaviva delle Fonti, Italy Ospedale San donato Arezzo, Italy A.O. G. Rummo Benevento, Italy Ospedale Bellaria Bologna, Italy Ospedale Senatore Antonio Perrino Brindisi, Italy A.O. Garibaldi Nesimadi Catania Catania, Italy Ospedale Civile di Faenza Faenza, Italy A.O.U. Arcispedale Sant'Anna di Ferrara Ferrara, Italy Ospedale Fabrizio Spaziani della ASL di Frosinone Frosinone, Italy Ospedale Umbero I Lugo, Italy Istituto Nazionale Tumori Milano, Italy A.O. Univeristaria Policlinico Modena, Italy Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico Napoli, Italy, 80131 Seconda Universita di Napoli Napoli, Italy Ospedale Silvestrini Perugia, Italy Ospedale S. Maria delle Croci AUSL di Ravenna Ravenna, Italy A.O. Bainchi Melacrino Morelli Osp. Riuniti Reggio Calabria, Italy Ospedale degli Infermi, P.O. Ospedale Civile Rimini, Italy Policlinico Umberto I Roma, Italy Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore Roma, Italy 收起 <<
NCT00459862	Advanced Malignant Mesotheliom... 展开 >>a Localized Malignant Mesothelioma Recurrent Malignant Mesothelioma 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 收起 <<

靶点	VEGFR1 VEGFR1, IC50:10 nM VEGFR3 VEGFR3, IC50:47 nM VEGFR2 VEGFR2, IC50:30 nM PDGFR PDGFR, IC50:84 nM
描述	VEGF/VEGFR (vascular endothelial growth factor vascular endothelial growth factor receptor) pathway plays a key role in tumor angiogenesis by promotion of vascular and lymphatic endothelial, as well as survival, and invasion, thus resulting in neovascularization, tumor growth and metastasis. In addition, blockade of additional proangiogenic receptor tyrosine kinases, including PDGFR and FGFR, may improve long-term clinical outcomes. Pazopanib is a pan VEGFR inhibitor with IC50 values of 10nM, 30nM and 47nM for VEGFR1, VEGFR2 and VEGFR3 (measured by HTRF), respectively, less potent to c-Kit, PDGFR, FGFR and c-Fms with IC50 values of 74nM, 84nM, 140nM and 146nM. In cellular studies, Pazopanib inhibited VEGF/bFGF-induced proliferation of HUVECs with IC50 value of 21nM/720nM, as well as potently inhibited VEGF-induced the phosphorylation of VEGFR-2 with IC50 value of ∼8nM. As prediction by the inhibition of VEGFR and FGFR, matrigel plug assay showed that once-daily oral administration of Pazopanib at dose of 30mg/kg and 100mg/kg inhibited angiogenesis by 57% and 83%, respectively, in female swiss nu/nu mice, as well as achieved tumor inhibition by 32%, 59% and 69% in HT29 xenograft, 16%, 35% and 55% in A375P xenograft, 99%, 102% and 110% in HN5 xenograft at dose of 10mg/kg, 30mg/kg and 100mg/kg^[1].
作用机制	Pazopanib is an ATP-competitive inhibitor of human VEGFR2.^[2]

CAS号	444731-52-6
分子式	C₂₁H₂₃N₇O₂S
分子量	437.52
SMILES Code	CN(C1=CC=NC(NC2=CC=C(C(S(N)(=O)=O)=C2)C)=N1)C3=CC4=NN(C(C)=C4C=C3)C
MDL No.	MFCD11616589

别名	GW786034; GSK-VEG10003; GW786034B
运输	蓝冰
InChI Key	CUIHSIWYWATEQL-UHFFFAOYSA-N
Pubchem ID	10113978

Daudi cell		Growth inhibition assay		Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=3.53164 μM	SANGER
human A172 cell		Growth inhibition assay		Inhibition of human A172 cell growth in a cell viability assay, IC50=3.7379 μM	SANGER
human A204 cell		Growth inhibition assay		Inhibition of human A204 cell growth in a cell viability assay, IC50=109.06 nM	SANGER
human A375P cells		Proliferation assay		Antiproliferative activity against human A375P cells in serum containing medium	18620382
human A427 cell		Growth inhibition assay		Inhibition of human A427 cell growth in a cell viability assay, IC50=1.98075 μM	SANGER
human A704 cell		Growth inhibition assay		Inhibition of human A704 cell growth in a cell viability assay, IC50=1.60323 μM	SANGER
human AN3-CA cell		Growth inhibition assay		Inhibition of human AN3-CA cell growth in a cell viability assay, IC50=10.05 nM	SANGER
human CAL-54 cell		Growth inhibition assay		Inhibition of human CAL-54 cell growth in a cell viability assay, IC50=3.28367 μM	SANGER
human CCF-STTG1 cell		Growth inhibition assay		Inhibition of human CCF-STTG1 cell growth in a cell viability assay， IC50=1.04981 μM	SANGER
human CGTH-W-1 cell		Growth inhibition assay		Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50=40.01 nM	SANGER
human Daoy cell		Growth inhibition assay		Inhibition of human Daoy cell growth in a cell viability assay, IC50=4.77949 μM	SANGER
human Daudi cell		Growth inhibition assay		Inhibition of human Daudi cell growth in a cell viability assay, IC50=3.66219 μM	SANGER
human DK-MG cell		Growth inhibition assay		Inhibition of human DK-MG cell growth in a cell viability assay, IC50=5.72028 Μm	SANGER
human DMS-273 cell		Growth inhibition assay		Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=4.96202 μM	SANGER
human EB2 cell		Growth inhibition assay		Inhibition of human EB2 cell growth in a cell viability assay, IC50=3.28168 μM	SANGER
human EoL-1-cell cell		Growth inhibition assay		Inhibition of human EoL-1-cell cell growth in a cell viability assay, ic50=2.89e-05 μM	SANGER
human ESS-1 cell		Growth inhibition assay		Inhibition of human ESS-1 cell growth in a cell viability assay, IC50=1.60396 μM	SANGER
human G-361 cell		Growth inhibition assay		Inhibition of human G-361 cell growth in a cell viability assay, IC50=3.04082 μM	SANGER
human G-401 cell		Growth inhibition assay		Inhibition of human G-401 cell growth in a cell viability assay, IC50=1.46421 μM	SANGER
human G-402 cell		Growth inhibition assay		Inhibition of human G-402 cell growth in a cell viability assay, IC50=531.84 nM	SANGER
human GDM-1 cell		Growth inhibition assay		Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=103.99 nM	SANGER
human GI-1 cell		Growth inhibition assay		Inhibition of human GI-1 cell growth in a cell viability assay, IC50=2.22951 μM	SANGER
human H4 cell		Growth inhibition assay		Inhibition of human H4 cell growth in a cell viability assay, IC50=2.51262 μM	SANGER
human HCC1395 cell		Growth inhibition assay		Inhibition of human HCC1395 cell growth in a cell viability assay, IC50=2.58156 μM	SANGER
human HLE cell		Growth inhibition assay		Inhibition of human HLE cell growth in a cell viability assay, IC50=1.63804 μM	SANGER
human HN5 cells		Proliferation assay		Antiproliferative activity against human HN5 cells in serum containing medium	18620382
human HT29 cells		Proliferation assay		Antiproliferative activity against human HT29 cells in serum containing medium	18620382
human HT55 cell		Growth inhibition assay		Inhibition of human HT55 cell growth in a cell viability assay, IC50=0.98781 μM	SANGER
human HUTU-80 cell		Growth inhibition assay		Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=1.28103 μM	SANGER
human IGROV-1 cell		Growth inhibition assay		Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=3.24713 μM	SANGER
human J82 cell		Growth inhibition assay		Inhibition of human J82 cell growth in a cell viability assay, IC50=2.06088 μM	SANGER
human KG-1 cell		Growth inhibition assay		Inhibition of human KG-1 cell growth in a cell viability assay, IC50=0.71755 μM	SANGER
human KGN cell		Growth inhibition assay		Inhibition of human KGN cell growth in a cell viability assay, IC50=4.06709 μM	SANGER
human KU812 cell		Growth inhibition assay		Inhibition of human KU812 cell growth in a cell viability assay, IC50=5.37812 μM	SANGER
human LB1047-RCC cell		Growth inhibition assay		Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=3.331368 μM	SANGER
human LB831-BLC cell		Growth inhibition assay		Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=2.54566 μM	SANGER
human LCLC-103H cell		Growth inhibition assay		Inhibition of human LCLC-103H cell growth in a cell viability assay	SANGER
human LK-2 cell		Growth inhibition assay		Inhibition of human LK-2 cell growth in a cell viability assay, IC50=2.64569 μM	SANGER
human MC-IXC cell		Growth inhibition assay		Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=1.11512 μM	SANGER
human MFE-296 cell		Growth inhibition assay		Inhibition of human MFE-296 cell growth in a cell viability assay, IC50=0.59022 μM	SANGER
human MG-63 cell		Growth inhibition assay		Inhibition of human MG-63 cell growth in a cell viability assay, IC50=1.00146 μM	SANGER
human MIA-PaCa-2 cell		Growth inhibition assay		Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50=5.60466 μM	SANGER
human MV-4-11 cell		Growth inhibition assay		Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=1.34501 μM	SANGER
human NCI-H2342 cell		Growth inhibition assay		Inhibition of human NCI-H2342 cell growth in a cell viability assay. IC50=3.13316 μM	SANGER
human NCI-H716 cell		Growth inhibition assay		Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50=2.31633 μM	SANGER
human NCI-H727 cell		Growth inhibition assay		Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50=5.40901 μM	SANGER
human NOS-1 cell		Growth inhibition assay		Inhibition of human NOS-1 cell growth in a cell viability assay, ic50=0.65987 μM	SANGER
human NY cell		Growth inhibition assay		Inhibition of human NY cell growth in a cell viability assay, IC50=1.84821 μM	SANGER
human P30-OHK cell		Growth inhibition assay		Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=5.4694 μM	SANGER
human RT-112 cell		Growth inhibition assay		Inhibition of human RT-112 cell growth in a cell viability assay, IC50=1.10376 μM	SANGER
human SF126 cell		Growth inhibition assay		Inhibition of human SF126 cell growth in a cell viability assay, IC50=2.47459 μM	SANGER
human SK-LU-1 cell		Growth inhibition assay		Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=3.18767 μM	SANGER
human SK-N-DZ cell		Growth inhibition assay		Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=2.02381 μM	SANGER
human SNG-M cell		Growth inhibition assay		Inhibition of human SNG-M cell growth in a cell viability assay, IC50=4.08669 μM	SANGER
human SW1710 cell		Growth inhibition assay		Inhibition of human SW1710 cell growth in a cell viability assay, IC50=4.47318 μM	SANGER
human TT cell		Growth inhibition assay		Inhibition of human TT cell growth in a cell viability assay, IC50=5.6624 μM	SANGER
HUVEC	1 μM	Function assay	6 h	Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 0.1 uM after 6 hrs by Matrigel assay	24036042

Pazopanib/帕唑帕尼 {[allProObj[0].p_purity_real_show]}

Pazopanib/帕唑帕尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pazopanib/帕唑帕尼质控信息

Pazopanib/帕唑帕尼生物活性

Pazopanib/帕唑帕尼细胞实验

Pazopanib/帕唑帕尼动物实验

Pazopanib/帕唑帕尼动物研究

Pazopanib/帕唑帕尼临床研究

Pazopanib/帕唑帕尼参考文献

Pazopanib/帕唑帕尼实验方案

Pazopanib/帕唑帕尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

VEGFR1	VEGFR1, IC50:10 nM
VEGFR3	VEGFR3, IC50:47 nM
VEGFR2	VEGFR2, IC50:30 nM
PDGFR	PDGFR, IC50:84 nM
FGFR	FGFR, IC50:74 nM
FGFR	FGFR, IC50:140 nM
c-Kit	c-Kit, IC50:140 nM
c-Kit	c-Kit, IC50:74 nM

Pazopanib/帕唑帕尼 {[allProObj[0].p_purity_real_show]}

Pazopanib/帕唑帕尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pazopanib/帕唑帕尼 质控信息

Pazopanib/帕唑帕尼 生物活性

Pazopanib/帕唑帕尼 细胞实验

Pazopanib/帕唑帕尼 动物实验

Pazopanib/帕唑帕尼 动物研究

Pazopanib/帕唑帕尼 临床研究

Pazopanib/帕唑帕尼 参考文献

Pazopanib/帕唑帕尼 实验方案

Pazopanib/帕唑帕尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pazopanib/帕唑帕尼纯度/质量文件产品仅供科研

Pazopanib/帕唑帕尼质控信息

Pazopanib/帕唑帕尼生物活性

Pazopanib/帕唑帕尼细胞实验

Pazopanib/帕唑帕尼动物实验

Pazopanib/帕唑帕尼动物研究

Pazopanib/帕唑帕尼临床研究

Pazopanib/帕唑帕尼参考文献

Pazopanib/帕唑帕尼实验方案

Pazopanib/帕唑帕尼技术信息